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The cardiac muscle ryanodine receptor (RyR2) is an intracellular Ca2+ channel responsible for 
the release of Ca2+ during excitation-contraction coupling. It is also implicated in pathological 
store-overload-induced Ca2+ release (SOICR), a common trigger for life-threatening 
arrhythmias. Phosphorylation plays a vital role in the modulation of RyR2 and SOICR, and 
recent work has outlined a possible relationship between a novel protein kinase, CK2 (formerly 
casein kinase II), and two RyR2 residues, S2692/93. The aim of this study was to investigate 
whether the interaction between these two RyR2 residues and CK2 leads to modification of 
RyR2 function and how this may impact SOICR susceptibility. 
A knock-in heterozygous S2692/93A (S2692/93A+/-) mouse model with modified RyR2 
residues preventing CK2-associated phosphorylation was generated. Confocal microscopy 
demonstrated that isolated S2692/93A+/- cardiomyocytes exhibited increased SOICR frequency 
compared with baseline. This was especially notable at lower extracellular Ca2+ levels; in these 
conditions, pacing induced a significantly higher SOICR frequency compared with baseline in 
S2692/93A+/- mice (0.082 ± 0.027 Sparks/100 µm/s-1, n = 8) compared with their wt littermates 
(0.003 ± 0.003 Sparks/100 µm/s-1, n = 5, p= 0.01). An in vivo analysis was conducted using 
both echocardiography and electrocardiogram to determine whether the cellular-level 
dysfunction seen in the S2692/93A+/- mice translated into an increased arrhythmia 
susceptibility. This analysis revealed no significant difference in key cardiac parameters at 
baseline or in response to acute pharmacological stress (adrenaline/caffeine) between 
S2692/93A+/- mice and their wt littermates. Taken together, these findings demonstrate for the 
first time that RyR2 can be phosphorylated at S2692/93 in vivo. Unlike previously identified 
RyR2-associated kinases such as calmodulin-dependent protein kinase II and calmodulin-
dependent protein kinase II, CK2-associated phosphorylation appears to have a 
cardioprotective effect, reducing SOICR propensity. Why this cellular dysfunction did not 
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    Introduction 
1.1. Cardiovascular disease and arrhythmia 
1.2. The cardiovascular system  
The cardiovascular system is responsible for the movement of vital nutrients, gases and 
hormones to cells around the body, and the subsequent removal of metabolic wastes. It also 
plays a major role in the regulation of body temperature, fluid pH, and water content of cells. 
Providing adequate perfusion ensures a constant supply of these vital components to the tissue, 
and adjusting pump output is vital to ensuring that homeostasis persists even with the changing 
metabolic demands of the body. Without the heart, and the contractile function it provides, these 
processes could not occur.  
1.2.1. Epidemiology of cardiovascular disease 
Cardiovascular disease (CVD) is predicted to become the number one cause of mortality 
worldwide by 2020; in 2015 the World Health Organisation implicated CVD in >17 million 
deaths worldwide. Within New Zealand, CVD accounts for >33% of all-cause-mortality and 
affects one in 20 adults (Health, 2015a). One of the leading causes of CVD mortality is 
arrhythmia (the irregular or uncontrolled contraction of the heart), which increases risk of 
mortality 11-fold in affected individuals (Jones, Guo, & Chen, 2017). CVD also represents a 
major health disparity in New Zealand, in 2010, the total CVD mortality rate was twice as high 
among Māori than the rest of the population (Health, 2015b), while individuals of Pacific Island 
descent were more likely to develop CVD than all other ethnic groups (Quirke, 2011). It is 
therefore clear that understanding these complex pathologies is vital to mitigate the burden of 
this global disease. 
1.2.2. Cardiac Excitation-Contraction coupling, Ca2+ induced Ca2+ release, and 
Ca2+ cycling 
Cardiac excitation-contraction (EC) coupling is a process by which cardiomyocytes convert 




potentials from the sinoatrial node and latent pacemakers in the atria travel down transverse (T) 
tubules, extensions of the cell membrane that permeate deep into the cardiac muscle fibre. 
Charge travelling within these tubules opens membrane-bound L-type voltage-gated calcium 
(Ca2+)  channels (LTCCs), triggering an influx of Ca2+ ions into the cell. Although not sufficient 
to initiate a contraction, the increased Ca2+ binds to the sarcoplasmic reticulum (SR)-bound 
ryanodine receptor (RyR2) channel, stabilising its open state and increasing open probability 
(PO) (Bers, 2002b). This allows further release of Ca2+  from the internal Ca2+ store (SR) in a 
process coined ‘Ca2+-Induced Ca2+ Release’ (CICR) (Fill & Copello, 2003). During a normal 
cardiac cycle, this Ca2+ release occurs from a single or a cluster of RyR2 channels, and is 
referred to as an evoked or triggered Ca2+ spark (Zhang et al., 2012). During the CICR process, 
Ca2+ influx through LTCCs leads to thousands of simultaneously triggered Ca2+ sparks from 
RyR2 channels known as a Ca2+ transient.  
This increased cytosolic Ca2+  then binds to the myofilament protein troponin-C, initiating 
contraction of the cardiomyocyte via the shortening of the functional sarcomere unit (Lanner, 
Georgiou, Joshi, & Hamilton, 2010), driving the mechanical contraction of the heart. It is the 
spatiotemporal summation of these Ca2+ sparks over a cardiomyocyte that gives rise to a 
uniform Ca2+ transient, allowing coupled contraction. Following EC coupling, myocyte 
relaxation is achieved via removal of Ca2+  from the cytosol. In most mammals, this is 
predominantly accomplished via Ca2+ re-uptake (~70%) into the SR by the SR ATPase pump 
(SERCA), and to a lesser extent through extrusion from the cell via the sodium (Na+)/Ca2+  
exchanger (28%) (NCX), the NCX is an electrogenic pump that moves one Ca2+ ion out of the 
membrane in exchange for three Na+ ions. The last protein responsible for the removal of Ca2+ 
from the cytosol is the mitochondria Ca2+ uniporter and sarcolemma ATPase (Bassani, Bassani, 
& Bers, 1994). Significantly, these mechanisms although well conserved across mammals vary 
slightly between species in the percentage Ca2+ clearance, with mice predominantly using 





Figure 1.1. Schematic of EC coupling within the cardiomyocyte. (1) Ca2+ enters the cardiomyocyte 
through L-type Ca2+ channel and binds to RyR, (2) Calcium-induced calcium release of SR Ca2+ into the 
cytosol (3) Increased cytosolic Ca2+ binds to troponin-c, allowing myofilament contraction (4) Ca2+ is 
removed from the cytosol via primarily SERCA into the SR as well as being extruded from the cell by 
electrogenic NCX. Smaller Ca2+ handling pathways, such as the Plasma membrane Ca2+ ATPase, and 
Mitochondrial Ca2+ uniporter are not shown. LTCC, L-type calcium channels; NCX, Na+/Ca2+ 
exchanger; RyR2, ryanodine receptor; PLB, phospholambam; SERCA, sarco/endoplasmic reticulum 
calcium ATPase; SR, sarcoplasmic reticulum. Original schematic created with Biorender, adapted from 
(Bers., 2002a). 
1.3. Pathological Ca2+ cycling 
1.3.1. Store-overload induced Ca2+ release  
The careful control of CICR demonstrates the importance of spatiotemporal modulation of Ca2+ 
ions, furthered by the complex cardiomyopathies that occur in its absence (Wehrens, Lehnart, 
Reiken, & Marks, 2004). RyR2 exhibits not only cytosolic Ca2+ sensitivity, but also luminal SR 
Ca2+ sensitivity. When SR-stored Ca2+  content reaches a critical luminal-threshold level, store 
overload induced Ca2+  release (SOICR) can spontaneously occur through RyR2, opening the 
channel and allowing a Ca2+ release event independent of CICR, sometimes referred to as a 
Ca2+ leak or a spontaneous Ca2+ spark (Figure 1.2) (Bai et al., 2013; W. Chen et al., 2014; 




as during excessive b-adrenergic stimulation, Na+ overload, elevated extracellular Ca2+  
concentrations and fast pacing of the heart (Bai et al., 2013; Lakatta, 1992). Normally the RyR2 
luminal SOICR threshold should not allow significant Ca2+  spillover events to occur, even 
during high stress or exercise conditions (Bers, 2002b), (Figure 1.2A-B.). However, pro-
arrhythmogenic drugs, along with some hereditary mutations (Jones et al., 2008; Liu et al., 
2010) and certain phosphorylation events on RyR2, have all been attributed to reducing the 
luminal SOICR threshold (Figure 1.2C-D.), thereby increasing propensity for Ca2+  leak (Jiang 
et al., 2010; Waddell et al., 2016).  
 
Figure 1.2. Schematic of SOICR events in normal and pathological situations. (A) Healthy cell with 
low SR Ca2+ loading, SOICR threshold sits significantly above SR Ca2+ load (B) SR Ca2+ load rises but 
does not reach the SOICR threshold. (C) Altered RyR2 protein, subsequently decreased SOICR 
threshold (D) Subsequently, stress situations lead to increased SR loading and surpassing of the SOICR 
threshold, leading to a SOICR event. RyR2, ryanodine receptor 2; SOICR, store-overload-induced Ca2+ 




1.3.2. Delayed afterdeporisations and Arrhythmia  
At the SR junction, the functional ensemble of LTCC, RyR2 and associated proteins are known 
as a Ca2+ release unit (CRU). The activation of a CRU by either physiological (CICR), or 
pathological (SOICR) Ca2+ release will produce a further Ca2+ spark from the CRU. It is 
important to note that spontaneous Ca2+ sparks (SOICR events) are seen within quiescent 
cardiomyocytes (Cheng, Lederer, Lederer, & Cannell, 1996), but in pathological conditions 
such as chronic SOICR, spark frequency can increase.  As an open RyR2 channel can 
potentially activate neighbouring RyR2 channels within a cluster, a spontaneous Ca2+ spark 
could represent the coordinated opening of all channels within the cluster, or just a single 
channel  (Sobie et al., 2006). 
Under conditions of Ca2+ overload, these sparks can coalesce to form Ca2+ waves, which 
represent the propagation of increased intracellular Ca2+ from one CRU to another (Cheng et 
al., 1996; Currie, Elliott, Smith, & Loughrey, 2011; Wasserstrom et al., 2010). Following a 
Ca2+ spark or wave event, increased cytosolic Ca2+ activates the NCX, which due to its 
electrogenic properties (one Ca2+ out, three Na+ in), bring Na+ into the cell, potentially 
depolarizing it, a phenomenon called a after depolarisation, depending on how early and 
prolonged an after depolarisation is, it can be classed as an early-after depolarisation (EAD) or 
a delayed-after-depolarisation (DADs).  Dependent on the size of a DAD, it can lead to the 
depolarisation of the cardiomyocyte, which spreads quickly through gap junctions to adjacent 
cells (Kong et al., 2008; D. Sato, Bartos, Ginsburg, & Bers, 2014). DADs represent a major risk 
factor for triggered arrhythmia and sudden death in heart failure (HF) patients.  
Arrhythmia itself is divided into several sub-types, with bradycardia and tachycardia being 
chronotropic terms used to describe either a slow or fast heart rate respectively. Fibrillation 
refers to the uncontrolled irregular contraction of the myocardium and is characterised 




treatment of arrhythmia depends on a number of preventative or control treatments, including 
implantable defibrillators, artificial pacemakers or medications (MOH., 2015).  
1.4. Diabetes mellitus 
One condition that has been implicated heavily in elevating Ca2+ leak and arrhythmia risk is 
Diabetes Mellitus (DM). A group of metabolic disorders characterised by elevated blood 
glucose levels (hyperglycaemia) and either reduced insulin production (type-I) or reduced 
insulin receptor sensitivity (type-II). By 2030, DM is expected to rise to the seventh-highest 
cause of mortality in humans, accounting for about 3% of all-cause mortality (Mathers & 
Loncar, 2006). Moreover, the debilitating aspects of DM, are predicted to become the  11th 
highest cause of disability-adjusted life years, affecting 328 million individuals by 2030 
(Mathers & Loncar, 2006). Individuals affected by DM also have an increased risk of CVD, 
exhibiting increased Ca2+ leak and arrhythmias (Agarwal & Singh, 2017; Movahed, 
Hashemzadeh, & Jamal, 2005; Zhao et al., 2006) and a substantially higher risk of CVD 
associated mortality (Morrish, Wang, Stevens, Fuller, & Keen, 2001).  
1.5. RyR2 
1.5.1. Structure of RyR2  
RyR2 channels are homotetramers made up of four identical 565-kD monomers that enclose a 
central ion-conducting pore. The RyR2 gene is encoded on chromosome 1q43 and spans 102 
exons, forming the largest ion channel in the body (Rouslan, Alexander, Ruedi, & Stefan, 
2014). The large cytoplasmic domains of RyR2 serve as a scaffold for diverse ligand 
interactions (Jones et al., 2017; Marx et al., 2000), and during channel activation, these 
peripheral regions undergo significant conformational changes (Peng et al., 2016; Rouslan et 
al., 2014). Initially, it was believed that only two factors could affect CICR: the amount of Ca2+ 
entering via the LTCC, and the activity of the SERCA pump (Eschenhagen, 2010). However, 
intrinsic RyR2 channel function is now understood to also play a key role, due to its vast 




proteins, such as FK506 binding protein (FKBP12.6), protein phosphatases 1/2A (PP1/2A), 
calmodulin (CaM) and sorcin (Error! Reference source not found.) (Fill & Copello, 2003; Marx 
et al., 2000; Peng et al., 2016). Additionally, luminal SR surface proteins such as triadin, junctin 
and calsequestrin 2(CSQ2) also act as Ca2+  buffers (Bers, 2002b; McFarland, Sleiman, Yaeger, 
& Cala, 2011), while cytosolic activation sites on RyR2 act as a scaffold for a variety of post-
translational modifications (PTMs) such as phosphorylation and oxidation (Peng et al., 2016).  
 
Figure 1.3. Structure of RyR2 with associated proteins. RyR2 is made up of four monomers, with 
modulators and regulatory proteins binding to the RyR2 tetramer (for simplicity are depicted here on 
only one monomer). SR luminal proteins calmodulin (CaM), calsequestrin 2 (CSQ2), junctin and triadin 
are thought to associate directly with the RyR2 monomers forming the Ca2+ release unit. Other 
associated proteins are believed to act on the large cytosolic domain. CaMKII, calmodulin/Ca2+-
dependent kinase II; FKBP, FKBP binding protein; LTCC, L-type Ca2+ channel; PKA, protein kinase 
A. Adapted from Lanner et al. (2010). 
1.5.2. FKBP 12.6 
FKBP12.6 is a 12 kDa SR binding protein that stabilises RyR2 channel function, facilitating 
coupled gating between neighbouring RyR2 channels within a cluster (Brillantes et al., 1994; 




has been proposed that hyperphosphorylation of RyR2 at serine (S)-2808 can lead to 
dissociation of FKBP12.6, thereby promoting instability of the FKBP12.6–RyR2 complex and 
aggregating SR Ca2+ leaks (Marx et al., 2000; Ono et al., 2000; Xiao et al., 2005), thus 
suggesting that FKBP12.6 plays a role in reducing spontaneous Ca2+ sparks (Gómez et al., 
2004). This concept is supported by genetic knock out (KO) mouse models, which 
demonstrated that depletion of FKBP12.6 resulted in leaky RyR2 channels, and diastolic Ca2+ 
leak (Gómez et al., 2004).  
1.5.3. CSQ2, triadin and junctin  
Three principal SR proteins confer RyR luminal Ca2+ sensitivity within the CRU: CSQ2, 
triadin, and junctin (Györke, Hester, Jones, & Györke, 2004). CSQ2 is a luminal SR protein 
that determines both the amount of Ca2+ released from this organelle during EC coupling, as 
well as overall SR Ca2+ storage (Y. Sato et al., 1998; Terentyev et al., 2003). Junctin and triadin 
play an important role in functionally transmitting signals between CSQ2 and the RyR2 channel 
(Dulhunty et al., 2012; Guo, Cala, & Song, 2012). Loss or altered expression of CSQ2 (Chopra 
et al., 2007; Guo et al., 2012), triadin (Gergs et al., 2007) or junctin (Altschafl et al., 2011; 
Gergs et al., 2007) has been implicated in elevated diastolic SR Ca2+ leak and arrhythmia 
susceptibility, demonstrating the importance of these proteins within the CRU.  
1.5.4. CaM 
CaM is a ubiquitous cytoplasmic Ca2+ sensor-messaging protein, that regulates intracellular 
Ca2+ and target proteins, either directly, or via their regulatory kinases and phosphatases 
(Quadroni et al., 1998; Xiong et al., 2018). CaM was the first peptide found to interact with 
single RyR channels, reducing its activity by up to 60% in animal models (Ai, Curran, Shannon, 
Bers, & Pogwizd, 2005; Xu & Meissner, 2004). The influence of CaM on RyR2 and several 
associated proteins, such as the Na+/H+ exchanger, nitric oxide synthase and SERCA (Benaim 




1.5.5. Sorcin and PP1/PP2 
Sorcin is a small binding protein associated with the RyR2 macromolecular complex (X. Chen 
et al., 2018; Meyers et al., 1995). During CICR it is believed to shut off the RyR2 channel and 
stabilise the Ca2+ transient (Farrell, Antaramian, Rueda, Gómez, & Valdivia, 2003). Another 
aspect of the RyR2 macromolecular complex is cardiac-specific PP1/2A, which co-localise 
with RyR2 at the SR membrane (Ai et al., 2005). PP1/2A have been shown to dephosphorylate 
the RyR2 channel complex and other associated proteins, depending on the relative kinase-
phosphatase balance (Vest et al., 2005). In turn, the extent of phosphorylation of RyR2, 
determines PO, and thus the amount of SR Ca2+ released during cardiac cycling (Marx et al., 
2000). 
1.5.6. Small binding molecules 
Both adenosine triphosphate (ATP) and caffeine interact with RyR2 in the same region as 
cytosolic Ca2+  (Waddell et al., 2016). It is believed that they can sensitise RyR2 to luminal Ca2+  
by destabilising the channel in a manner similar to cytosolic Ca2+  activation. It has been 
suggested that ATP is an activator of RyR channels alongside various other adenine nucleotides 
(adenosine-diphosphate/monophosphate) that also potentiate SR Ca2+  release but are less 
effective than ATP (Lanner et al., 2010). In the absence of cytosolic Ca2+, RyR2 requires ATP 
or caffeine for effective luminal Ca2+  activation (Jones et al., 2017). Conversely, cytosolic 
magnesium  is a potent inhibitor of the RyR2 channel and is believed to act via two distinct 
mechanisms: by reducing PO through competing with Ca2+  at its cytosolic activation site (Fill 
& Copello, 2003), or alternatively, by increasing interaction between RyR2 and CaM (Dong et 
al., 2017). This results in shifting of the channel’s Ca2+ sensitivity, requiring a higher level of 
luminal Ca2+ to initiate a SOICR event (Fill & Copello, 2003). 
1.6. PTMs 
Previous studies have outlined the extensive regulation of RyR2 by its various accessory 




have been demonstrated in pathological conditions to increase spontaneous Ca2+ sparks 
(Dobrev & Wehrens, 2010; Erickson et al., 2013; B. Xiao et al., 2007). Phosphorylation, in 
particular, has been shown to significantly regulate RyR2 activity due to the numerous 
phosphorylation sites located on RyR2. 
1.6.1. Oxidation 
Oxidation has been heavily implicated in augmenting cardiac dysfunction via alteration of 
RyR2 function, (Eager & Dulhunty, 1998; Goldhaber & Liu, 1994; Jones et al., 2017). One 
study recently used a human embryonic kidney cell (HEK293) line to demonstrate the temporal 
and spatial changes in RyR2 with increasing oxidation levels. It was found that whilst low levels 
of reactive oxygen species (ROS) led to a decrease in the SOICR threshold, higher 
concentrations increased the threshold, reducing the frequency of Ca2+  spark events (Waddell 
et al., 2016). This biphasic effect was attributed to changes in luminal Ca2+  sensitivity of RyR2, 
with those thiol groups easily accessed by ROS initially decreasing the SOICR threshold and 
inducing a conformational change, but those requiring prolonged exposure causing a loss of 
RyR2 activity. It was also proposed that the conformational change that occurred within RyR2 
following initial oxidation could expose novel residues to oxidation, also accounting for this 
biphasic response of the channel. Despite this persuasive evidence of the role of oxidation in 
pathological Ca2+  leak, there is still a resounding absence of in vivo models to support this 
hypothesis.  
1.6.2. Phosphorylation 
In addition to the regulation of  RyR2 by protein–protein interactions, small molecules, and 
oxidation, it is also modulated by site-specific phosphorylation. Numerous kinases have been 
identified as able to phosphorylate RyR2. Perhaps the most intensely studied have been the 
S/threonine (T) kinases: CaM/Ca2+-dependent kinase II (CaMKII) and protein kinase A (PKA). 
Physiologically, β-adrenergic stimulation activates both PKA and CaMKII, which 




2004). However, these kinases have also been implicated in cardiac dysfunction and 
arrhythmogenesis (Wehrens et al., 2004).  
PKA is generally accepted to augment diastolic Ca2+ leak from RyR2 via chronically increasing 
the PO of the channel. However, the specific sites and the method of action is a point of 
contention. The literature describes two main models to explain the action of PKA on RyR2: 
the Marks–Wehrens model (Figure 1.4A) and the phosphorylation hot-spot model (Figure 
1.4B).  Both models suggest that PKA is upregulated with chronic β-adrenergic stimulation and 
has a crucial role to play in diastolic Ca2+ leak.  
The Marks–Wehrens model is based upon early animal studies and implicates increased PKA 
activity leading to hyper-phosphorylation of RyR2 at S2808. Hyperphosphorylation of RyR2 
at S2808 is believed to reduce the binding affinity of FKBP12.6, inducing sub-conductance 
states in RyR2 and increasing its sensitivity to cytosolic Ca2+, which in turn increases PO 
(Dobrev & Wehrens, 2010; Marx et al., 2000). Other studies have been unable to confirm that 
S2808 phosphorylation changes drastically in HF conditions (Eschenhagen, 2010), or even at 
all (G. Y. Li, Kranias, Mignery, & Bers, 2002). Some research has demonstrated that even 
complete removal of FKBP12.6 does not significantly impact channel conductance (J. Xiao et 
al., 2007). New insights were obtained from S2808-KO mouse studies, which supported the 
conclusion that PKA hyperphosphorylation at this site leads to cardiac dysfunction (Shan, 
Betzenhauser, et al., 2010). Conversely, similar studies in S2808-KO mice demonstrated that 
increased PKA activity did not translate into altered cardiac responses, RyR2 gating or 
spontaneous Ca2+ sparks (Benkusky et al., 2007; Macdonnell et al., 2008).  
The phosphorylation hot-spot model was created in response to identification of another 
putative PKA phosphorylation site at RyR2-S2030 in both normal and pathological conditions. 
Phosphorylation at this site led to increased Ca2+ leak (Valdivia, 2012; B. Xiao et al., 2007). 




methodological differences between animal model studies (Eschenhagen, 2010). Hence, whilst 
the Marks–Wehrens model is based on high-quality data, it is not a unanimously held belief 
that PKA activity at S2808 alone is responsible for increased SOICR propensity. The model 
fails to acknowledge compelling data on the presence of multiple RyR2 phosphorylation sites, 
including most notably S2030 (Respress et al., 2012; Valdivia, 2012), and fails to consider the 
role that PP1/2A loss might play in RyR2 channel leakage (El-Armouche et al., 2006; Marx et 
al., 2000; Neef et al., 2010; Vest et al., 2005). 
CaMKII is responsible for the phosphorylation of several key Ca2+ handling proteins, including 
LTCCs, RyR2 and the SERCA-inhibitory protein phospholamban (Dobrev & Wehrens, 2010; 
Wehrens et al., 2004). Several studies have demonstrated that CaMKII levels increase during 
HF (Valdivia, 2012; Wehrens et al., 2004), supported by work on CaMKII over-expressing 
mice, which exhibit an increased risk of SR Ca2+ leak and cardiac arrhythmias (Neef et al., 
2010; Valdivia, 2012). CaMKII was originally proposed to directly act on RyR2 at S2814, 
reducing SOICR threshold and increasing RyR2 PO (Shan, Kushnir, et al., 2010; Valdivia, 
2012; Wehrens et al., 2004). However, work by Respress et al. (2012) found that genetic 
inhibition of S2814 phosphorylation could protect against non-ischemic but not ischemic HF, 
suggesting that a different pathological mechanism is responsible for inducing each of these 
conditions. Others have suggested that although S2814 represents a major site of action, 
CaMKII could also act at S2030 and S2808 (Macdonnell et al., 2008; Wehrens et al., 2004).  
Taken together, this emerging evidence demonstrates that RyR2 diastolic SR Ca2+ leak is a 
complex interplay between multiple diverse PTMs and protein interactions. While many 
researchers support a phosphorylation ‘hot-spot’ model (Chelu et al., 2009; Valdivia, 2012) to 
explain the differential changes to RyR2, ongoing research has only continued to outline 
discrepancies in the sites and proposed actions of these complex protein-protein interactions. 




that S2030 is a PKA site, S2814 is a CaMKII site and S2808 can be phosphorylated by both 
PKA and CaMKII (Macdonnell et al., 2008; Wehrens et al., 2004; Zhang et al., 2012). 
 
 
Figure 1.4. Schematic models of proposed RyR2 phosphorylation profiles. (A) Marks-Wehrens 
model of RyR2 leak, with PKA acting on S2808 and causing the dissociation of FKBP12.6, whilst 
CaMKII acts on S2814. Combined these kinases either directly, or via intermediates (FKBP12.6) 
induced increased PO within the channel (B) Multi-phosphorylation site model of RyR2 leak with several 
different sites having an effect on the conductance of RyR2 channel. This hotspot contains a number of 
residues believed to be phosphorylated by a range of different kinases, with some acting at multiple 
sites. CaMKII calcium/calmodulin-dependent protein kinase II; HF, heart failure; PKA, protein kinase 
A; PKG, GMP-dependent protein kinase; PO, open probability; PSR, sarcoplasmic reticulum; RyR2, 
ryanodine receptor 2. Taken from (Valdivia, 2012).  
1.7. Protein kinase CK2  
CK2 is an essential, highly conserved, ubiquitously expressed S/T kinase made up of two 




control over the catalytic activity of the CK2α subunit, acting as an inhibitor of the catalytic 
subunit (Bosc et al., 2000; Litchfield, 2003). CK2 displays a spectrum of activities, playing a 
key role in protein translation and differentiation (Murtaza et al., 2008). Like other kinases, 
CK2 can be modulated by several diverse stimuli including phosphorylation, regulated 
assembly and various protein–protein interactions. CK2 is believed to be constitutively active 
and is one of the most prolific kinases within the body, delivering a high basal rate of 
phosphorylation to its target proteins (Chakraborty, 2018; Litchfield, 2003). Whilst CK2 
isoforms, such as CK2a and CK2a’ exhibit different functions, they are mostly associated with 
cellular processes such as transcription, translation, morphogenesis, and cell cycle progression. 
However, CK2 also exhibits wider functions, such as modulating cardiac hypertrophy, 
apoptosis, cytoskeletal formation, and various cardiac–associated proteins (Bosc et al., 2000; 
Hauck et al., 2008).  
1.7.1. Role of CK2 in, tumorigenesis, apoptosis and hypertrophy 
Alongside its physiological actions in cellular process, CK2 dysfunction has been implicated in 
several pathologies. It is been well established that CK2 displays increased expression within 
rapidly proliferating tissues (Guerra & Issinger, 1999), with elevated CK2 levels being 
observed in prostate, lung and kidney cancers (Gyenis & Litchfield, 2008; Litchfield, 2003). 
Robust and compelling studies have shown that CK2 phosphorylates the apoptosis repressor 
with caspase recruitment domain (ARC) in vivo and in vitro at T149, (Li et al., 2002; Murtaza 
et al., 2008) preventing cardiac apoptosis (Litchfield, 2003).  ARC forms a critical aspect of the 
catalase-CK2-ARC pathway (Figure 1.5); a reduction in any of these proteins results in 
widespread cellular apoptosis (Li et al., 2002). One study mimicked the effects of hypertrophic 
stimuli, a known cause of catalase inhibition via small interfering ribonucleic acid (siRNA) 
knockdown, leading to increased ROS formation and carbonylation of CK2s catalytic domain, 




ARC phosphorylation and increased cellular apoptosis, a trend seen commonly in HF patients 
(Li et al., 2002). 
CK2 has also been identified as a major player in the cardiac hypertrophy pathway, one crucial 
aspect of which is tumour suppressor p27, a potent inhibitor of CK2 and major growth regulator 
(Hauck et al., 2008). It has been suggested that in situations of increased hypertrophic stimuli, 
CK2 phosphorylates p27 at S83 and T187, leading to its degradation via ubiquitylation (Hauck 
et al., 2008). The result is enhanced CK2 activity and the formation of a feedback loop, leading 
to further hypertrophy (Burton, Yacoub, & Barton, 1999; Hauck et al., 2008).   
 
Figure 1.5. Effect of hypertrophic signalling on CK2 and apoptosis. Hypertrophic stimuli leads to 
the loss of Catalase, resulting in the formation of reactive oxygen species. This, in turn, leads to the 
oxidative modification of CK2, which prevents it from phosphorylating ARC, resulting in apoptosis and 
cell death. ARC, apoptosis repressor with caspase recruitment domain; CK2, protein kinase CK2; ROS, 
reactive oxygen species. Taken from Murtaza et al. (2008). 
1.7.2. Modulation of CaM, and CSQ2 
CSQ2 is a highly phosphorylated protein, and CK2 knockdown studies have demonstrated 
diminished CSQ2 kinase activity and increased Ca2+ leak from RyR2, suggesting that CK2 is 
an in vivo kinase for CSQ2 (Guo et al., 2012; McFarland et al., 2011). This would imply at least 
an indirect relationship between CK2, and RyR2, with CK2 affecting luminal Ca2+ gating via 




luminal Ca2+ (W. Chen et al., 2014), suggesting other factors could be involved, including a 
potential direct relationship between CK2 and RyR2. 
It is well established that CK2 is likely to be the kinase responsible for CaM phosphorylation, 
which then regulates RyR2 either directly, or indirectly via associated CaM dependent kinases 
such as CaMKII (Benaim & Villalobo, 2002; Fill & Copello, 2003). It has been proposed that 
CK2 has an inhibitory effect on CaM. Phosphorylated CaM exhibits a reduced binding affinity 
for associated proteins (Quadroni et al., 1998), which is believed to have an over-reaching 
inhibitory effect on RyR2 channel function (Benaim & Villalobo, 2002). However, there 
remains discrepancy over the site of action of CK2 at CQS2, highlighting the limited current 
understanding of CK2 function (Benaim & Villalobo, 2002; Xiaojun Huang et al., 2013; 
Quadroni et al., 1998). 
1.7.3. Effect on RyR2  
Previous research has focused mainly on the effects of well-characterised kinases, such as PKA 
and CaMKII, on RyR2 and SOICR threshold, in vivo studies highlighting the extensive role 
both proteins play in cardiac dysfunction. However, while these kinases clearly contribute 
towards the overall pathology and RyR2 dysfunction, ongoing research has also indicated that 
they alone cannot explain all changes observed in channel function and pathologies such as 
arrhythmia. The role that CK2 plays in the modulation of CSQ2 and RyR2 luminal Ca2+ 
sensitivity, alongside its prolific activity on previously identified targets, suggests the 
possibility of a direct relationship between CK2 and RyR2. This prospect forms the basis of 
much of the present thesis.   
Novel and preliminary data from the Jones laboratory (unpublished) has identified that in 
HEK293 cell lines, CK2 endogenously phosphorylates RyR2 independently of its action via 
CSQ2. HEK293 cells expressing RyR2 exhibit SOICR events, and it was found that reducing 




tetrabromobenzotriazole increased the propensity for these SOICR events to occur. Mass 
spectrometry was used to identify two novel phosphorylation sites on RyR2 specifically 
targeted by CK2 in HEK293 cells: S2692 and its neighbour S2693. Further analysis of these 
sites revealed a high basal level of phosphorylation, which is in keeping with the belief that 
CK2 is constitutively active and acting on these sites under normal physiological conditions 
(Bosc et al., 2000; Litchfield, 2003).  
These preliminary data suggest that in contrast to the actions of PKA or CaMKII, which have 
been suggested to increase the propensity for SOICR events (Shan, Betzenhauser, et al., 2010; 
Shan, Kushnir, et al., 2010; Valdivia, 2012; Wehrens et al., 2004; Wehrens et al., 2006), CK2 
phosphorylation of RyR2 appears to reduce the propensity for SOICR and potentially protect 
against DADs. This conclusion is further supported by data obtained from HF patients, who 
have reduced CK2 levels (Li et al., 2002; Murtaza et al., 2008) and phosphorylation of RyR2 
at S2692/93 (Chakraborty, 2018). These functional data suggest that RyR2 requires high levels 
of basal phosphorylation at S2692/93, and during HF conditions the loss of CK2 activity at 
these critical sites, alongside the actions of PKA and CaMKII, results in increased SOICR 
events and arrhythmia (Figure 1.6). Therefore, preservation or restoration of CK2 levels in HF 






Figure 1.6. Schematic representation of the effect of Cardiac disease on kinase levels and SOICR. 
Increasing severity of cardiac disease leads to increased levels of PKA/CaMKII, both of which in turn 
increase their phosphorylation of RyR2, leading to increased diastolic Ca2+ leak. Conversely, cardiac 
disease decreases the levels of CK2 in vivo, reducing its phosphorylation at S2692/93, and in turn 
leading to increased SOICR propensity. CK2: casein Kinase 2, SOICR: store-overload induced Ca2+ 
release, PKA: protein kinase A, CaMKII: CaM/Ca2+ kinase II Original figure created with Biorender.  
1.8. Project rationale 
There is currently a limited understanding of many PTMs acting on the RyR2 channel. The aim 
of this research was to provide an insight into the role that CK2-mediated phosphorylation 
might play in the overall modulation of the RyR2 channel. Preliminary research by the Jones 
Lab (unpublished) has identified several cardiac diseases in which it is believed a loss of CK2 
phosphorylation is present; however, this has never been examined within an in vivo model. It 
is hoped that this project will add to this growing body of evidence, towards a better 
understanding of the role of the RyR2 channel in arrhythmia, and will contribute to the possible 
future development of a new targeted approach to the treatment of arrhythmia, including in HF 
patients. 
1.8.1. Aims 
The aim of this research project was to investigate the potential role of phosphorylation on 





- To investigate whether CK2 has a functional effect on RyR2 at S2692/93: to date, 
there is no published evidence of such a direct relationship between CK2 and RyR2. This 
potential relationship was analysed with the aid of Western blotting. 
- To determine the effect of a chronic loss of CK2-associated phosphorylation at 
S2692/93. This was achieved using both pharmacological and genetic inhibition methods, 
alongside in vitro and in vivo analysis tools. 
1.8.2. Hypotheses 
It was initially hypothesised that in various forms of cardiac disease, blocking S2692/93 
phosphorylation would induce an increased propensity for Ca2+ spark events and SOICR at the 
cellular level. If such changes were exhibited at the cellular level, it was further hypothesised 






    Materials and Methods 
A variety of analysis techniques was used throughout this project. Western blotting was used 
to quantify protein expression changes in Zucker diabetic fatty (ZDF) rat tissue lysates. 
Electrocardiogram (ECG) and Echocardiography (Echo) were used as an in vivo measure of 
functional and electrical changes within the CK2 transgenic animals, which alongside a stress 
test, functioned as an assessment of arrhythmic susceptibility. A Langendorff apparatus was 
used to isolate individual cardiomyocytes, which were then loaded with Ca2+-sensitive dye for 
imaging. Confocal imaging under various conditions was performed on isolated myocytes from 
both CK2 transgenic and wildtype (wt) mice to determine individual changes in cellular Ca2+.  
2.1. ZDF Rat samples 
The ZDF rat is a leptin-resistant (homozygous fa/fa leptin receptor-deficient) animal model of 
type 2 diabetes. ZDF rats are obese (Wang, P, & Pippin, 2014) and exhibit hyperphagia 
(Kowalski, Ster, & Smith, 1998), hyperglycaemia (Triscari, Stern, Johnson, & Sullivan, 1979), 
hyperinsulinemia (Trimble, Bruzzone, & Belin, 1986), and hyperlipidaemia (Sparks et al., 
1998). All tissue samples in this project were obtained from the right ventricle (RV) of ZDF 
rats aged an average of 20 weeks. Cell lysates were prepared under a standardised protocol by 
Chindima Okolo, Dr Akash Deep Chakraborty or Sajida Parveen (Jones Lab) using a well-
established laboratory protocol (Chakraborty, 2018) and cryopreserved at -80°C until use.  
2.2. Western Blotting of protein extract from the RV of ZDF rats. 
2.2.1. Gel casting  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS PAGE) was carried out 
using the standard protocol of Laemmli (1970) in order to separate proteins of interest-based 
upon molecular weight. This allowed Western blotting analysis to quantify the protein of 
interest within the sample. Gel casting plates (Bio-Rad) were used to cast acrylamide gels of 
various percentages (either 6% or 10%), with 1.5 mm spacers. A resolving gel (Table 2.1) was 




Q was subsequently removed and a stacking gel (Table 2.2) was cast over the resolving gel 
with a 10 or 15 well comb placed into the stacking gel to form protein loading wells. The 
stacking was left to polymerise for 45 minutes.  
Table 2.1. Resolving Gel 
Ingredients  6% gel (µL)  10% gel (µL)  Supplier  
MilliQ-water 4632  3832  Lab supply  
Tris/HCl (1.5 M, pH 8.8)  2000  2000  VWR Global Science  
Acrylamide/bis acylamide (40%, 
37.5:1)  
1200  2000  Bio-Rad  
Sodium dodecyl sulphate (10%)  80  80  Thermo Scientific  
Ammonium persulphate (10%)  80  80  Sigma  
Tetramethylethylenediamine 8  8  Acros Organics  
Table 2.2. Stacking Gel 
Ingredients  % gel (µL)  Supplier  
MilliQ-water  5032  Lab supply  
Tris/HCl (0.5 M, pH 6.8)  2000  VWR Global Science  
Acrylamide/bis acylamide (40%, 37.5:1)  800  Bio-Rad  
Sodium dodecyl sulphate (10%)  80  Thermo Scientific  
Ammonium persulphate (10%)  80  Sigma  
Tetramethylethylenediamine 8  Acros Organics  
2.2.2. Sample preparation and loading 
Samples were stored in a -80°C freezer, where the lysates could remain viable for long periods 
of time. Prior to use, samples were placed in a water bath at room temperature to thaw. Once 
thawed, the loading volume was determined according to a lysate’s specific protein 
concentration, with all samples lanes loaded with 70 µg of each sample. A 15 µL aliquot of 2x 
Laemmli buffer (Table 2.1) was added to each sample and MilliQ-H2O was used to top up the 
sample to the 30 µL required volume. Despite only 20 µL of prepared sample being added to 
the protein loading wells, the volume was made up to 30 µL sample to adjust for the expected 
loss of around 30% during heating. Lysate samples were then vortexed, centrifuged at 16,000×g 




Table 2.3. 2 x Laemmli buffer 
Ingredients  Concentration Supplier 
Tris/HCl (pH 6.8)  125 mM VWR Global Science 
Sodium dodecyl sulphate  4% (w/vol) Thermo Scientific  
Glycerol  20% (w/vol)  VWR Global Science  
2-Mercaptoethanol  10% (w/vol)  Sigma  
Bromophenol blue  0.004% (w/vol)  Sigma  
2.2.3. SDS-Page 
Following incubation, samples were centrifuged before loading to remove insoluble material. 
A vertical electrophoresis tank (Bio-Rad) was filled with 1x  running buffer (Appendix One, 
Table 0.1), and the gel placed securely into the tank. The protein loading wells were then loaded 
with 20 µL aliquots of sample within the gel alongside a protein ladder (8 µL of Precision plus 
protein dual colour, Biorad), which was run along with the sample lanes to function as a 
molecular weight marker. The samples were separated at a constant voltage (60 V) (TIC 
Powerpack, BioRad) until the bromophenol blue dye had reached the end of the stacking gel, 
signalling that the samples had passed through it. At this point, the voltage was increased to 
120 V to further separate the proteins. Running time for an individual gel was dependent upon 
the molecular weight of the protein and the percentage gel used. Typically, 6% gels ran for 4–
7 hours, and 10% gels for 2–3 hours.  
2.2.4. Wet Transfer  
The proteins from the SDS–PAGE were transferred onto a nitrocellulose membrane with a pore 
size of 0.45 µM  (Bio-Rad) using a wet transfer technique, whereby the gel and membrane are 
sandwiched between two pieces of blotting paper (Thermo scientific) and sponge fibre pads 
within a cassette (Towbin, Staehelin, & Gordon, 1979) (Error! Reference source not found.). 
The blotting cassette was carefully assembled, ensuring that no air bubbles remained by rolling 
each layer and then placed into a transfer tank with the membrane facing the anode and the gel 
facing the cathode. The transfer tank was filled with transfer buffer (Appendix One, Table 




performed at a constant voltage (54 V) for 8-12 hours overnight, with the magnetic stirrer set 
to 100 rpm. Transfer was conducted at 4ºC in a cold room to prevent overheating and gel 
swelling, which could damage samples.  
 
Figure 2.1. Representative image of Wet Transfer method. Gel and membrane are placed between 
two pieces of filter paper, with the membrane facing the anode and the gel facing the cathode, they are 
in turn placed within a sandwich of filter paper and fibre pads, which is then placed into the cassette. 
Image taken from Licor (2019).  
2.2.5. Blocking and Antibody wash 
Once the transfer was complete, the membrane was removed from the cassette and washed 
three times with a 0.5% Tween-20 phosphate-buffered sale (PBS) solution (1x PBS-T) 
(Appendix One, Table 0.3) and then washed in 1x PBS for 5 minutes each, to remove residual 
transfer buffer and other gel pieces. Thereafter, the membrane was blocked in 5% (w/v) bovine 
serum albumin (BSA) dissolved in 1x PBS-T for phosphor antibodies (Appendix One, Table 
0.4), or 5% (w/v) non-fat milk powder dissolved in 1x PBS (Appendix One, Table 0.5) for 
total protein antibody 34C. The membrane was blocked in these solutions for 2 hours at room 
temperature followed by a triple wash in 1x PBS-T for 5 minutes each, and a single wash in 1x 




This was followed by incubation of the membrane in the primary antibody solution ( 
Table 2.4) for 4 hours at room temperature, followed by washing of the membrane in 1x PBS-
T thrice for 5 minutes each, then once for 5 minutes in 1x PBS. The membrane was then 
incubated in the relevant horseradish peroxidase labelled species-specific secondary antibody 
(Table 2.5) for 2 hours at room temperature. This was followed by another triple wash in 1x 
PBS-T for 5 minutes, then once in 1x PBS for 5 minutes. Throughout the entire protocol, the 
membrane was gently rocked at 60 rpm.  
Table 2.4. Primary antibody solutions.  
Primary Antibody  Dilution  Species  Diluent Supplier  
Total RyR2 (34C) 1:1000  Mouse  80% PBS, 20% FBS [vol/vol], 




1:200 Rabbit  80% PBS, 20% FBS [vol/vol], 
0.02% NaN3 (w/vol) 
Badrilla  
Table 2.5. Secondary antibody solutions. Prepared in PBS. 
Secondary Antibody Dilution  Species  Diluent Supplier  
Anti-Mouse  1:20000  Goat  PBS  Abcam  
Anti-Rabbit  1:20000  Goat  PBS Abcam  
 
Table 2.6. Schematic of different protocols used for each gel. 
Wash step 1 Wash step 2 Primer Primary antibody 
Secondary 
antibody 
3 x 5 min in [1x PBST]  1 x 5 min in [1x PBS] 5% Milk in 
PBS 
34C Anti-mouse 
3 x 5 min in [1x PBST]  1 x 5 min in [1x PBS] 5% BSA in 
PBST 
619  Anti-rabbit 
BSA, bovine serum albumin; PBS, phosphate-buffered saline; PBS-T 0.5% Tween phosphate-buffered 
saline 
2.2.6. Detection and Imaging  
All antibody labelled proteins were detected using enhanced chemiluminescence (ECL) 
solution, made by adding 2 mL of SuperSignal® West Pico Luminol / Enhancer Solution with 
2 mL SuperSignal® WestPico Stable Peroxide Solution (Thermo Scientific). The ECL solution 
was then applied to the membrane, covering it completely for 5 minutes at room temperature. 
The excess reagent was removed, the membrane was placed in between two transparent plastic 




using SynGene PXi4 imaging system (SynGene). Using SynGene, the blot option was selected, 
followed by Chemi Blot (single image). The exposure time was varied to obtain an 
appropriately exposed image (over-exposure was automatically determined by the gene tools 
software).  
2.2.7. Densitometry  
Images were exported from the SynGene system and analysed using Studio Lite Ver 5.2 (LiCor) 
software where background labelling was subtracted. For the semi-quantification of 
modification, labelling was normalised against total RyR2 expression labelled with 34C. 
Densitometry calculations were conducted, and raw values exported to Microsoft Excel to be 
normalised against total RyR2 level (34C). Normalised data were then entered onto GraphPad 
Prism version 7.  
2.3. Ethical Approval 
All animal studies were approved by the University of Otago Animal Ethics Committee and 
were performed in accordance and compliance with the Animal Welfare Act (1999) and the 
University's Code of Ethical Conduct. Either C57BL/6 (C57) mice, and transgenic 
heterozygous S2692/93A+/-  mice or wt control littermates (age 8 – 12 weeks) were used for all 
experiments. Animal welfare training was also conducted prior to starting experimental work.  
2.4. In vivo Animal Experiments 
The C57 model used in this study is an inbred laboratory strain of mice, which has the 
advantages of being stable and easy to breed. These animals will henceforth be referred to as 
C57 mice in this report. The C57 mice were initially used as training animals to practice 
techniques and optimise the protocol; C57 mice were also used for single-cell work involving 
CK2 blocker tetrabromocinnamic acid (TBCA) (see 2.6.2.1). Transgenic heterozygous 
S2692/93A+/- Knock-in (KI) animals were generated using the well-established CRISPR/Cas9 
technology at the transgenic core facility at Australia National University, which has been used 




directed mutagenesis was used to substitute the phosphate accepting S residue to alanine (A) to 
prevent phosphorylation at this site. Once initial mice were obtained from Australia National 
University, a colony was established at the University of Otago. These KI mice will be referred 
to as ‘S2692/93A+/-’ mice throughout this thesis; their wt littermate controls will be referred to 
as ‘wt’ mice. Both male and female mice were used in the experiments, however, due to the 
requirement for more females to continue breeding and expand colony size, there was a slight 
gender bias towards males. All mice (C57, S2692/93A+/-and wt littermates) were housed under 
a 12-hour lighting schedule with access to normal mouse chow and water ad libitum. All 
S2692/93A+/- and wt mice used in these experiments were between 8 – 12 weeks of age at the 
time of the experiment.  
2.4.1. Genotyping of S2692/93A+/- mouse model 
To verify the genotype of individuals within the mouse colony for experiments, tail tips from 
the colony were used for DNA extraction and Polymerase Chain reaction (PCR). This aspect 
of the project was carried out by Dr Akash Deep Chakraborty (Jones Lab), and the genotype of 
individual mice withheld to allow blinding during the experimental and analysis phases of the 
project.  The ear notches obtained from the transgenic animals were lysed and incubated in lysis 
buffer (100 mM Tris base, 5 mM EDTA, 20% SDS, 200 mM NaCl) containing 1 µL of 
proteinase K (20 mg/mL), each ear notch sample was used as a template for PCR. The PCR 
products were separated on a 1% agarose gel and the DNA bands obtained were cut into 
individual tubes. The DNA from the gel was extracted using NucleoSpin gel and PCR cleanup 
kit (Macharey Nagel). Following this, the extracted DNA was sent for sequencing (genetic 
analysis services, Otago) using specific sequencing primers to look for the genotype of each 
animal to differentiate between wild type and mutant animals and set up breeding pairs. 
2.4.2. Anaesthesia 
Mice were initially weighed, to calculate body weight (BW), and then placed in a Perspex 




oxygen (O2) per minute. Following the loss of righting reflex, anaesthetised mice were placed 
on a heating pad (28 °C) to maintain core body temperature and head placed in nose cone for 
continued iso flow. Deep plane anaesthesia was determined by loss of pedal reflex response. 
Tape was used to secure the mice in a supine position (Figure 2.2), to allow unimpeded access 
to the ventral aspect of the chest and abdomen. Iso levels were adjusted (0.5 – 2%) throughout 
the experiment to maintain optimal respiratory patterns whilst maintaining plane of anaesthesia.  
2.4.3. Stress test 
To promote the induction of ventricular arrhythmias in S2692/93A+/- mice, all animals were 
subjected to an induced stress test to assess arrhythmia susceptibility and alterations in cardiac 
function. Following a period of baseline recording, mice were administered an acute 
intraperitoneal (i.p.) injection of adrenaline (1.6 mg/kg) and caffeine (120 mg/kg). These doses 
were consistent with that used in previous studies (Cerrone et al., 2005; Kannankeril et al., 
2006), and was believed to be a more comprehensive method for determining arrhythmia 
susceptibility, compared with an exercise protocol.   
2.4.4. ECG recordings 
Thirteen animals, 8 S2692/93A+/- mice, and 5 wt littermates were assessed for their 
susceptibility to drug-induced arrhythmias using ECG recordings. ECG is a diagnostic tool that 
is routinely used to assess the electrical function of the heart by recording electrical activity 
generated by the heart muscle depolarisations, which propagate in pulsating electrical waves 
towards the skin. These waves can be picked up by recording electrodes, which can then be 





A two-lead ECG acted as a heart monitor for this project, measuring the rate and rhythm of the 
heartbeat. Following loss of the pedal reflex, acupuncture needles (Tai-Chi) acted as electrodes 
for our Lead II ECG recording. These electrodes were inserted subcutaneously into the limbs 
to provide subdermal recordings (Error! Reference source not found.), with the positive 
electrode on the right-forelimb, the negative electrode on the left-hindlimb and the grounding 
electrode on the right-hindlimb. These signals were recorded using a using Power Lab 
(ADInstruments), with consistent settings (sampling rate 10 k/s, range 10 mV, Low pass 200 
Hz, High pass 0.3 Hz, mains filter on, anti-alias on). ECG was monitored under anaesthesia for 
around 5–10 minutes prior to stress test to provide time for a baseline recording and allow the 
heart rate to stabilise under anaesthesia. 
 Stress test ECG 
Following the acute stress test injection, ECG was continuously monitored for 60 minutes, to 
provide a comprehensive stress response for each animal. However, if the animal displayed a 
significant inability to sustain either heart rate or respiratory rate, the experiment was 
terminated and the mouse was immediately euthanised and progressed to Langendorff 
perfusion for cardiomyocyte isolation.  
Figure 2.2. Representative image of ECG and Echo configuration. Electrodes were connected to 
right fore-limb (positive), left hind-limb (negative), and right hind-limb (ground) to provide a lead II 
ECG, information was then passed through a Bio-Amplifiyer and LabChart.  Echocardiography was 
recorded using a E9 Cardiac ultrasound system with a ML6-15 linear array transducer on MM setting. 
Original figure made on Paint.net. R: Right fore-limb, L: Left fore-limb, F: Right hind-limb, + : positivie 





All animals that undertook ECG analysis were also studied with Echo to accessed systolic and 
diastolic function and determine overall functional changes within the heart. To achieve this, 
anaesthetised mice had chest hair removed using hair removal cream (Veet) and cleaned with 
wet wipes. Mice were imaged in a supine position, with the probe placed on the left hemithorax 
interfaced with a layer of ultrasonic transmission gel (Parker). Short-axis Echo measurements 
were used to assess systolic and diastolic function, and a two-dimensional parasternal short-
axis imaging plane was used as a guide for obtaining left ventricle (LV) M-mode tracings close 
to the papillary muscle level (Figure 2.2). Images were taken using the ML6-15 linear array 
transducer (GE Healthcare Vivid E9 Cardiac Ultrasound system) under ‘Mouse-Rodent’ 2D 
MM setting with a frame rate of 300 frames per second and a bandwidth of 4.5 – 150 MHz. For 
each scan, a minimum depth setting of 2 cm was used with a sweep speed of 100 mm s−1. M-
mode is defined as time-motion display of the ultrasound wave along a chosen ultrasound line 
that provides a monodimensional view of the heart.  
 Echo stress test procedure 
Following administration of caffeine and adrenaline to induce the stress test as described 
previously (Section 2.4.3.Stress test), Echo measurements were taken at 2, 5, 15, 30, 45 and 60 
minutes post-injection. This allowed the analysis of functional changes within the heart over an 





Figure 2.3. Example Echo measurement from preliminary findings. Representative images taken 
from a single wild-type mouse both pre and post-stress test protocol (A) Baseline, (B) 30 seconds post-
stress test (C) 2 minutes post-stress test (D) 4 minutes post stress test. X-Axis represents time, Y-axis is 
M-Mode recording. Original figure.  
2.4.6. Offline data analysis 
 Percentage time in Non-sinus rhythm and Arrhythmia scoring 
LabChart 8.0 software (ADinstrument) was used to identify arrhythmogenic events (EADs, 
DADs and bigeminy) occurring within the heart. EADs were identified as any incomplete 
relaxation followed by a premature ventricular contraction (PVC), while DADs were identified 
as any complete relaxation followed by a PVC, both DADs and EADs were regarded as PVCs. 
An event was considered a bigeminy event if it had 4 or more peaks and those peaks alternated 





Figure 2.4. Examples of normal and arrhythmic events within murine lead II ECG trace (A) Sinus 
rhythm and (B) Unsustained bigeminy in a single mouse pre and post-stress text. (C) Sustained bigeminy 
(D) example of PVCs (EAD and DAD) and monomorphic VT. (E) Unsustained period of Ventricular 
tachycardia (VT) / Ventricular fibrillation. (F) Sustained bi-directional VT. * denotes a non-sinus 
rhythm event. Original figure.  
To measure percentage time spent in sinus rhythm; five minutes pre-stress test, and every 
minute post-stress test was analysed individually, with the number of beats out of sinus rhythm 
and heart rate being used to calculate a percentage of arrhythmic beats per unit time Equation 
2.1. Calculating percentage arrhythmic beats within ECG trace.Equation 2.1). 
Equation 2.1. Calculating percentage arrhythmic beats within ECG trace. 
 
The overall animal arrhythmia level was also evaluated and based on a five-point arrhythmia 
score adapted from (Curtis & Walker, 1988). This allowed characterisation of the animal’s 




Table 2.7. Arrhythmia scoring system, based over 60-minute post-stress timeframe and adapted 
from Curtis and Walker (1988) 
Arrhythmia score Characteristics 
0 <50 PVCs (no arrhythmias or isolated PVCs)  
1 60 – 250 PVCs (very occasional EADs or DADs)  
2 250 – 1000 PVCs (frequent PVCs) (un-sustained bigeminy) 
3 >1000 PVCs (sustained bigeminy) or 1 – 2 episodes of V-Tach  
4 V-Tach present 
5 Ventricular fibrillation or death 
V-tach: ventricular tachycardia, PVCs: premature ventricular contractions, EADs: early after-
depolarisations, DADs: delayed after depolarisations.  
 Analysing Echo data 
Values for systolic and diastolic cardiac parameters were determined using inbuilt Vivid E9 
Cardiac Ultrasound system analysis software. Regular beats seen within the Echo trace were 
used to calculate contractile interval, alongside the interventricular septum thickness, left 
ventricle internal diameter and posterior wall thickness in both diastole and systole (Figure 
2.5Figure 2.2). Data represent the average of at least three separate scans, with each scan 
representing the average of 5 selected beats.  
 
Figure 2.5. Echo analysis example. On each image, five measurements of Interventricular Septal 
thickness at diastole (IVSd) and systole (IVSs), Left-Ventricular internal diameter at diastole (LVIDd) 
and systole (LVIDs), and posterior wall thickness at diastole (PWd) and systole (PWs) would be taken, 
this would be repeated for three images, creating 15 separate data points for each post-stress time point. 




This data can be calculated to determine a number of different cardiac parameters. These 
included; fractional shortening (FS), end-diastolic volume (EDV), ejection fraction (EF), end-
systolic volume (ESV), LV internal dimensions in diastole (LVIDd) and systole (LVIDs), end-
diastolic LV posterior wall thickness (LVPWd), end-systolic LV posterior wall thickness 
(LVPWs), interventricular septum thickness at end-systole (IVSs), interventricular septum 
thickness at end-diastole (IVSd), stroke volume (SV), cardiac output (CO), heart rate (HR), and 
R–R interval. This data would then be exported into an excel spreadsheet file for analysis within 
GraphPad Prism 7 software.  
2.5. Isolation of individual Cardiomyocytes 
2.5.1. Euthanasia and surgery 
Following the completion of in vivo functional assessments by ECG and Echo, mice were 
euthanised by cervical dislocation and hearts exposed via thoracotomy. The hearts were quickly 
excised and cannulated Langendorff apparatus so as to isolate single ventricular 
cardiomyocytes under the collagenase type II (Worthingtons) method (Wolska & Solaro, 1996). 
Post-Mortem, a thoracotomy was performed to expose the thoracic and abdominal cavities 
(Figure 2.6A), and the heart removed. First, a large incision was made just inferior to the 
xiphoid process following the line of the lower boundary of the ribs moving outwards toward 
the right forelimb, thus exposing the abdominal cavity. Next, a blunt dissection technique was 
used to cut through the diaphragm and the ribs were trimmed away via an incision along the 
right-hand side lateral aspect of the sternum. This surgical technique exposes the heart with 




   
Figure 2.6 (A) Mouse incision diagram. (1) Primary incision from the xiphoid process, along the 
posterior aspect of ribcage. (2) Secondary incision along the lateral aspect of sternum toward neck, 
exposing the thoracic cavity.  (B) Heart removal schematic. Clamp point and incision line used for 
removal of the heart outlined. Original figure made on Paint.net.  
The heart was then excised by clamping down on the branches of the aorta (Figure 2.6B.), and 
finely trimming beyond the clamp whilst gently pulling the heart upwards and outwards. This 
technique was used to best preserve the aorta for cannulation and prevent damage. Once 
removed, the heart was trimmed of excess tissue (thymus/lung) and placed in a weigh boat 
filled with calcium-free Krebs HEPES-bicarbonate-based buffer (KRH) ( 
Table 2.8) at 4◦C to allow measurement of heart weight (HW). Other measurements were taken 
in the post-mortem period including individual kidney weight (KW), body weight (BW) and 
tibial length (TL).  
Table 2.8. 6 mM Glucose KRH solution. Final pH; 7.38 – 7.42 
Ingredients  Concentration (mM) Supplier (w/v) 
HEPES 25 VWR Global Science 
NaCl 125 Lab Supply 
D-Glucose 12 Sigma 
KCL 5 Sigma  





2.5.2. Langendorff perfusion   
A Langendorff perfusion system is an ex vivo retrograde system allowing gravity perfusion of 
the myocardium via the coronary vasculature. It is designed in such a manner as to supply the 
heart with sufficient oxygen and nutrients in order to maintain its viability and function outside 
the body. The Langendorff apparatus comprises of a blunt end 23-gauge cannula, 
thermostatically controlled water bath (Julabo), two temperature-controlled reservoirs with 
oxygenators (bubbled with 100% O2), and a bubble trap/compliance chamber (Error! Reference 
source not found.). Within the context of this study, the Langendorff apparatus allowed 
perfusion of the coronary vasculature with enzymes that could break down and isolate 
individual cardiomyocytes for use. 
Following removal of the heart, the aorta is cannulated on the 23-gauge cannula mounted to a 
Langendorff perfusion system. The period between excision and cannulation was kept as low 
as possible to prevent degradation of heart tissue and function (~3 minutes). The heart was 
secured to the cannula with a small loop of surgical thread and perfused with 37◦C Ca2+-free 
KRH buffer for 3–4 minutes. Following the clearance of blood and potential clots from the 
coronary vasculature, a 0.2 mM KRH-Ca2+ solution containing 50.5 mg collagenase 
(Worthington, 198 U mg−1, batch number #45M16096) is perfused through the heart to allow 
digestion of the cardiac tissue. After around 10–15 minutes digestion time, collagenase was 
turned off and digestion of the heart stopped.   
 Suspension and Ca2+ raising steps 
Following digestion, the ventricular tissue was cut away from the cannula and suspended in 10 
mL 0.15 mM KRH-Ca2+ solution. Scissors were used to cut the ventricular tissue into smaller 
pieces, with the larger chunks forming a pellet, and the supernatant poured off into a 15 mL 
tube. Another 10 mL of 15 mM KRH-Ca2+ solution was added, and after gentle titration to mix 
ventricular tissue with the solution, the supernatant was again poured off into a 15 mL tube. A 




mL samples suspended in 0.15 mM KRH-Ca2+ solution. Following analysis of cell viability and 
sample density on a light microscope, the most viable tubes were then combined to provide a 
greater cell tissue density. After allowing time for the myocytes to gravity settle, the supernatant 
was reduced, and 1 mM KRH-Ca2+ solution was added to raise the Ca2+ concentration to 0.25 
mM. The cell pellet was re-suspended in the KRH buffer and cells allowed to re-settle. This 
method was repeated to raise the extracellular Ca2+ concentration stepwise from 0.25 to 0.5, 
0.75 and finally 1.0 mM KRH-Ca2+ at room temperature, this method was employed to prevent 
cell death from large changes in extracellular Ca2+.  
2.6. Confocal imagining of isolated cell myocytes  
2.6.1. Confocal microscope set-up  
Confocal laser scanning microscopy (CLSM) is an optical imaging technique which can be 
used to visualise structures that can be fluorescently labelled. It massively increases the 
resolution, contrast and quality of a photomicrograph, yielding two-dimensional images that 
contain spatial information in one dimension and temporal information in the second 
dimension. Following Ca2+ raising, cells were checked for viability on a light microscope. 
Subsequently, 1mL of freshly isolated ventricular myocytes suspended in 1 mM KRH-Ca2+ was 
added to an Eppendorf tube wrapped in foil and loaded with 1µL 2 mM Fluo-4, AM (Thermo-
scientific). Cells were loaded for 20 min at room temperature and allowed to gravity settle. 
After 20 minutes, around 800 µL of supernatant was removed, and cells re-suspended in 800 
µL of 1 mM KRH-Ca2+. Loaded cells were added to a glass coverslip pre-mounted to a 
recording chamber upon a Nikon A1+ Inverted Confocal laser scanning microscope (Kurobane 
Nikon Co.). This confocal microscope was equipped with a 60 x WI objective, multi-channel 
perfusion system, temperature control jacket (Warner instruments), waste pump (Langer) and 





Figure 2.7. Confocal microscopy set up. (A) Langer waste pump (B) Nikon A1+ Inverted confocal 
microscope (C) Warner instruments temperature control jacket (D) Gravity perfusions system (E) SD9 
medical grass stimulator (F) Custom imaging/perfusion bath.  
2.6.2. Imaging 
Fluo-4 AM expressing ventricular cardiomyocytes selected for imaging were quiescent in the 
presence of 1 mM KRH-Ca2+, had a characteristic rod shape with no malformation of the 
contractile machinery, and responded (contracted) to 1 Hz stimulation at between 40–60 V. 
During imaging, these cells were constantly perfused using a gravity-flow system, and waste 
removed by a pump perfusion system. The Fluo-4 loaded myocytes were then excited using the 
488 nm argon laser and the fluorescence emission at 500-550 nm was recorded with confocal 
line-scans (LS) performed along the longitudinal axis of cells for selected time periods (see 
2.6.2.1 and 2.6.2.2). To minimise indicator photobleaching, Fluo-4 was excited with minimum 
laser energy. Cells were imaged under identical microscope settings (Scan speed: 512 Hz / 1.8 
ms ms/line, Pin-hole size: 1 AU, wavelength: 488 nm, dimensions: 512 x 5632). Line-scan 
images were processed with NIS-Elements AR 4.0 software and Fiji, an open-source image 





 LS of isolated cell myocytes in C57 cardiomyocytes treated with TBCA  
 
TBCA was used as a selective inhibitor of CK2 in-situ, as it shows greater affinity for CK2 
compared with other inhibitors such as 4,5,6,7-tetrabromobenzotriazole, which have off-target 
effects upon other existing kinases (Pagano et al., 2007). Within these experiments, C57 mouse 
line cardiomyocytes were isolated and initially perfused with room temperature 1 mM KRH-
Ca2+. Cells were paced between 40 – 60 V at 0.5 Hz for 1 minute to achieve a baseline recording, 
pacing was then stopped, and a baseline un-paced recording was taken. Myocytes were then 
washed for 4 minutes under constant pacing (40 – 60 V, 0.5 Hz), in a 1 mM KRH-Ca2+ solution 
containing either dimethyl sulphoxide (DMSO) (vehicle control), 100 nM TBCA (TBCA100) or 
500 nM TBCA (TBCA500) dissolved in DMSO. Both paced and un-paced recordings were taken 
at 2 and 4 minutes (Error! Reference source not found.Figure 2.8). Following this, a 1 mM 
KRH-Ca2+ solution containing 20 mM Caffeine (Sigma-Aldrich) was used in an un-paced 
condition to evaluate total SR Ca2+ store release capacity.  
 
Figure 2.8. Line scanning protocol for isolated wild-type TBCA treated cardiomyocytes. Line 
scanning (LS) of cardiomyocytes treated with TBCA or DMSO, myocytes were paced to achieve a 
baseline LS, then pacing was removed to achieve an un-paced baseline reading. Drug condition 
(DMSO/TBCA) was then perfused over the cardiomyocyte with both paced and un-paced LS’ were 
taken at 2 minutes and 4 minutes. DSMO: Dimethyl sulphoxide, TBCA: Tetrabromocinnamic acid. 
Original figure made on Paint.Net.  
 Confocal imagining of isolated cardiomyocytes in S2692/93A+/- mice 
Under each set of experiments, cells were perfused with KRH buffer containing either 1.8 mM, 
3 mM, or 5 mM Ca2+ at 37°C. Healthy cells were stimulated at between 40 – 60 V current and 
for 30 seconds at increasing frequency of stimulation from 1 Hz, to 3 Hz, and finally 5 Hz, and 




final 10 second of each 30 second interval. Finally, cells were continuously stimulated at 1 Hz 
whilst being perfused with a 1 mM KRH-Ca2+ + 20 mM Caffeine (Sigma-Aldrich) solution 
until a clear Ca2+ wave was observed and then dissipated.  
   
Figure 2.9. Line scanning protocol for S2692/93A+/- and wild-type littermates. Cells were 
continuously perfused with varying concentrations of KRH-Ca2+ (1.8, 3 or 5 mM KRH-Ca2+) whilst 
pacing for 30 seconds at increasing frequencies, rising from 1 Hz to 5 Hz, then returning to 1 Hz. Finally, 
cells were paced and perfused with 1 mM KRH-Ca2+ + 20 mM Caffeine to measure store content. LS’ 
were taken in the final 10-second of each 30-second interval. Original figure made on Paint.Net.  
This protocol was adapted throughout the project to help improve data available for analysis; 
several animals towards the finish were tested on a slightly altered protocol (Figure 2.10), 
which included un-paced periods. This was done to increase the level of Ca2+ sparks and waves 
seen, as it was believed the previous protocol’s (Figure 2.9) high pacing could be masking Ca2+ 
release events. Under this protocol, cardiomyocytes were perfused at 1.8 mM, 3 mM or 5 mM 
KRH-Ca2+, and paced at the same four levels of stimulation as in the previous protocol. 
However, following each 30 second pacing interval a second un-paced LS was taken followed 
by a 30 second un-paced period, before another 20 second LS.  
 
Figure 2.10. Updated line scanning protocol for S2692/93A+/- and wild-type littermates. Cells were 
continuously perfused with varying concentrations of KRH-Ca2+ (1, 3 or 5 mM KRH-Ca2+) whilst 
pacing for 30 seconds, in the final 10 seconds of this interval a line scan (LS) was taken, and then pacing 
was halted and another LS was conducted. The cell was then left un-paced for 30-seconds and then 
another LS was taken for 20 seconds. This protocol was repeated at increasing frequencies for a single 
cardiomyocyte, rising from 1 Hz to 5 Hz, then returning to 1 Hz. Finally, cells were paced and perfused 




2.6.3. Off-line analysis of line scan data 
The line-scan images were processed with the NIS-Elements AR 4.0 and analysed with 
SparkMaster, an automated Ca2+ spark analysis plug-in for ImageJ. This plug-in was developed 
by Picht, Zima, Blatter, and Bers (2007), and is based upon the original automated Ca2+ spark 
analysis software of Cheng et al. (1999). To exclude false-positive results, a threshold of 3.8 
was set for spark detection by the software. SparkMaster acts as an analysis algorithm that 
detects and quantifies both general image parameters such as number of detected sparks and 
spark frequency (sparks (100 µm)-1), as well as individual spark parameters such as amplitude 
(ΔF/F0); full width at half-maximum amplitude (FWHM; µm), full duration at half-maximum 
amplitude (FDHM; ms), full width, full duration, time to peak, maximum steepness of spark 
upstroke, and a time constant of spark decay. Other measures taken include amplitude (ΔF/F0) 
of Ca2+ release events and rate of Ca2+ rise (ms), both of which are measures of RyR2 release. 
These measures are normalised to the lowest diastolic Ca2+ levels (F0) seen prior to a 
contraction, helping to account for differential Fluo-4 AM loading within cells. The effect of a 
high dose of Caffeine (20 mM) was also be used to access Ca2+ store content.  
2.7. Statistical analysis  
Prism 8 (GraphPad) statistical analysis software was used to analyse all data and plot all 
graphs. All results were presented graphically as mean ± standard error of the mean (SEM). 
Non-parametric one-way ANOVA with post hoc test, two-way ANOVA, multiple t-tests and 
two-tailed unpaired student’s t-test were used for statistical comparison. The threshold for 




    Results 
 
The aim of this research project was to investigate the role of phosphorylation in modifying the 
properties of RyR2 and its potential role in SOICR events. It was hypothesised that two sites 
within RyR2, S2692 and S2693, were vital sites used by CK2 in modulating SOICR threshold. 
It was believed that a loss of phosphorylation at these sites could lead to reduced SOICR 
threshold, increased Ca2+ spark events, and by extension, DADs and arrhythmia. 
The primary focus of this project was to examine how PTMs such as phosphorylation could 
alter RyR2 function, and the role that protein kinase CK2 might play in this process within 
healthy and disease conditions. To achieve this, Western blotting of ZDF DM animals was used 
to examine changes in RyR2 phosphorylation brought about by DM. The second aspect of this 
project focused on the effect of acute pharmacological inhibition of CK2 within C57 
cardiomyocytes, through use of TBCA, an effective CK2 blocker, changes in cellular Ca2+ 
cycling and release could be analysed using confocal microscopy.  
The third and final section of the results pertains to the findings from the S2692/93A+/- 
transgenic mouse model. This KI model allows an in-depth analysis of chronic inhibition at the 
S2692/93 phosphorylation sites. The consequence of this block was assessed via in vivo 
analysis using Echo and ECG, followed by isolation of single cardiomyocytes for confocal 
imaging. It was hypothesised that S2692/93A+/- mutant mice would display adverse health 
outcomes when compared with their wt littermate controls, exhibiting increased SOICR events, 
and arrhythmia, thus demonstrating the importance of CK2 phosphorylation at these two crucial 




3.1. Western Blotting 
3.1.1. RyR2 phosphorylation at S2692/93 was not altered in DM ZDF rats  
Previous work within the Jones lab has shown that CK2 phosphorylation levels are reduced 
within human LV samples during HF with reduced EF (HFrEF) (unpublished data). It was 
hypothesised that a similar trend could be identified in chronically hyperglycaemic (DM) 
patients, which have been shown to exhibit increased Ca2+ leak and arrhythmias (Agarwal & 
Singh, 2017; Movahed et al., 2005; Zhao et al., 2006). To determine the effect of CK2 
phosphorylation changes under normal and diabetic conditions, protein samples were extracted 
from the LV of 18- to 22-week-old DM ZDF and from their non-DM (N-DM) ZDF littermate 
controls. The protein was then separated by Western blotting, and probed using the anti-
phospho-S2692/93 antibody 619, which recognises the phosphorylation status of these sites. 
The density of the RyR2 band labelled by this phosphorylation antibody was normalised to the 
respective total RyR2 level, as detected by antibody 34C. It was hypothesised that RyR2 
phosphorylation at the S2692/93 sites would decrease in the diabetic condition, which would 
result in a reduced labelling density detected with the 619 phospho antibody. 
As shown in Figure 3.1A. RyR2 expression was not consistent between samples. Great 
difficulty was encountered in achieving representative blots with both anti-phosphorylated 
antibody 619 and anti-total RyR2 antibody 34C. Densitometric analysis revealed no significant 
difference in labelling density between the N-DM and DM groups when detected with 619 





Figure 3.1. Level of phosphorylation modified RyR2 in ZDF left ventricle tissue (A) Representative 
Western blot images showing RyR2 S2692/93 phosphorylation level (619) and relative expression level 
(34C) in both diabetic (DM) and non-diabetic (N-DM) rat lysate samples within a 10% gel run for 2.5 
hours. (B) Densitometric analysis of RyR2 phosphorylation expression from DM and N-DM rat LV 
samples normalised to their respective total RyR2 level. n = 3 lysates. All results are shown as mean ± 
SEM. Statistical analysis was performed using two-tailed unpaired t-test and no statistical difference 
was achieved. N-DM: Non diabetes mellitus, DM: diabetes mellitus, 619: S2692/93 phospho-antibody, 
34C: total RyR2 antibody. 
3.2. Pharmacological inhibition of CK2 in TBCA treated wt cardiomyocytes 
The lack of change in phospho-S2692/93 levels observed in ZDF rats led to the decision to 
pharmacologically (artificially) block CK2 in vitro. Given that CK2-associated phosphorylation 
at S2692/93 is reduced in HFrEF patients (Jones lab., unpublished data), it was hypothesised 
that pharmacological blocking of CK2 would increase the level of SOICR events at the cellular 
level.  TBCA is a pharmacological inhibitor of CK2 in vitro (Pagano et al., 2007), and represents 
a method by which to selectively block the action of CK2 within isolated cardiomyocytes in a 
relatively acute timeframe. To elucidate whether acute TBCA treatment would result in 
increased SOICR events, C57 mouse cardiomyocytes were isolated via Langendorff perfusion 
and loaded onto a confocal microscope (Section 2.5). Cells were initially perfused with 1 mM 
KRH-Ca2+ at room temperature to induce a baseline cellular response, then for 4 minutes in 1-
mM DMSO (control), TBCA100 or TBCA500, loaded within a DMSO solution. Confocal LS’ of 
both paced and un-paced periods were taken to measure both the response of isolated 
cardiomyocytes to stimulation, and the characteristics of any Ca2+ sparks observed. It was 
hypothesised that a loss of associated CK2 phosphorylation would induce higher levels, and 




3.2.1. TBCA did not induce significant changes in the Ca2+ transient 
As changes in Ca2+ release are intrinsically linked to changes in cardiomyocyte contraction, the 
relationship between TBCA treatment and the Ca2+ transient profile was explored. Two 
measurements were used to quantify the Ca2+ transient: amplitude (ΔF/Fo) and time to peak 
transient fluorescence (ms). ΔF/Fo represents the change in fluorescence intensity relative to 
the diastolic fluorescence intensity, and is calculated for each image using a simple algorithm 
(Equation 3.1), where F(stim) is the peak intensity of the Ca2+ indicator in each image, and 
F(rest) is the intensity before electrical stimulation. Time to peak is a measure of the time taken 
between the F(rest) and peak F(stim) time points and represents a measure of the speed of Ca2+ 
release from the RyR2 channel.  
Equation 3.1. Calculating amplitude (ΔF/Fo) 
 
Whilst being perfused with KRH, there was no significant difference in amplitude (ΔF/Fo) 
(Figure 3.2A.) and time to peak transient fluorescence (Figure 3.2B.) between DMSO and 
TBCA treated groups, indicating that these cells were comparable at baseline. After 2 minutes 
of exposure to either DMSO or TBCA, the DMSO- and TBCA100-treated groups exhibited 
relatively similar ΔF/Fo values compared with baseline (DMSO: 1.044 ± 0.68 fold-change; 
TBCA100: 0.825 ± 0.19 fold-change); however, there appeared to be a relative increase in the 
Ca2+ transient amplitude in the TBCA500-treated cells (3.228 ± 1.25 fold-change). There was no 
significant difference between DMSO- and TBCA100-treated (p = 0.98), or between DMSO- 
and TBCA500-treated cells (p = 0.16). After 4 minutes of perfusion, DMSO-treated cells 
exhibited a trend towards reduced ΔF/Fo when compared with baseline (0.31 ± 0.17 fold-
change), while TBCA100-treated cells (1.122 ± 0.74 fold-change), and TBCA500-treated cells 
appeared to trend towards a relative increase compared with baseline (2.21 ± 1.8 fold-change). 
With no significant difference between DMSO- and TBCA100-treated (p = 0.82), or between 




Regarding the time to peak data, at 2 minutes; there was no significant alteration from baseline 
in the DMSO- and TBCA100-treated cells, and while the TBCA500-treated cells did exhibit a 
trend towards increased time to peak (1.67 ± 0.46 fold-change) relative to baseline, there was 
no significant difference in time to peak compared with the DMSO-treated cells (1.148 ± 0.44 
fold-change, p = 0.61). After 4 minutes of perfusion, DMSO and TBCA100-treated cells 
exhibited a tendency towards a slightly reduced time to peak compared with baseline (DMSO: 
0.795 ± 0.225 fold-change; TBCA100: 0.444 ± 0.007 fold-change); TBCA500-treated cells still 
exhibited increased time to peak relative to baseline levels (1.923 ± 1.1 fold-change). Again, 
however, none of these changes was statistically different from one another.  
Overall, these results suggest that treatment with TBCA (TBCA100 or TBCA500) does not appear 
to confer any significant changes in transient amplitude or time to peak compared with DMSO. 







Figure 3.2. Calculated transient data for wild-type mice treated with either DMSO or TBCA. All 
results collected from C57 mice (n = 2), and isolated cells were treated with either, 1 mM DMSO (n = 
3 cells), 100 nM TBCA (n = 5), or 500 nM TBCA (n = 6) for 4 minutes (C) Ca2+ transient amplitude 
(ΔF/Fo) pacing data (D) Time to peak. All values were normalised to baseline (KRH). Results are shown 
as mean ± SEM. Analysis was performed using a two-way ANOVA with Dunnett's post hoc test. ΔF/Fo: 
Transient amplitude, DSMO: Dimethyl sulfoxide, TBCA: Tetrabromocinnamic acid, TBCA100: TBCA 
100nM, TBCA500: TBCA 500 nM. 
3.2.2. Characterisation of Ca2+ sparks 
Given that TBCA did not alter the Ca2+ transient, the next step was to examine the impact of 
TBCA upon unstimulated (SOICR) Ca2+ release. Since these Ca2+ sparks represent a form of 







































































SOICR event, their quantification and analysis can indicate whole-cell propensity for DADs 
and triggered arrhythmia. Ca2+ spark analysis was conducted to measure the frequency, and size 
of sparks within isolated cardiomyocytes. Measurements were taken at baseline, whilst cells 
were perfused with 1 mM KRH-Ca2+ buffer, and after 4 minutes of perfusion in 1 mM DMSO, 
TBCA100 or TBCA500 in either 1 Hz paced or un-paced conditions. To achieve this, the 
automated Ca2+ spark analysis plugin SparkMaster (ImageJ) was used (Picht et al., 2007) , 
which automatically detects and analyses Ca2+ sparks, allowing quantification of various spark 
parameters. In the interests of brevity, spark frequency, as well as amplitude, and full-width 
half maximum (FWHM) were used as measurements of Ca2+ spark frequency and size. Within 
each cell, these were normalised to spark parameters observed at baseline perfusion with 1 mM 
KRH-Ca2+ to account for variations in Fluo-4 loading, cell health and length of LS.   
3.2.3. Ca2+ sparks in paced periods 
After 4 minutes of perfusion, a single measure of Ca2+ sparks was taken during a 10-second, 1 
Hz paced line-scan. Figure 3.3. shows the normalised change from baseline in DMSO, 
TBCA100- and TBCA500-treated cells. Spark frequency appeared to increase with higher 
concentrations of TBCA, While the DMSO group exhibited a trend towards decreased spark 
frequency compared with baseline (0.6 ± 0.26 fold-change), both the TBCA100 (1.231 ± 0.36 
fold-change) and TBCA500 (2.69 ± 1.085 fold-change) groups displayed increased Ca2+ spark 
frequency compared with baseline. However, the differences between the three treatment 
groups were not statistically significant (DMSO vs TBCA100, p = 0.853; DMSO vs TBCA500, 
p = 0.17; TBCA100 vs TBCA500, p = 0.369). Spark amplitude remained relatively constant 
between the three treatment groups, with each appearing to exhibit a decreased spark amplitude 
when compared with baseline; however, the differences between groups were not statistically 
significant. Similarly, there were no significant differences between any of the groups regarding 




change) and TBCA500-treated (1.549 ± 0.47 fold-change) cells and appearing to decrease in 
TBCA100-treated cells (0.9735 ± 0.13 fold-change). 
 
   
Figure 3.3. Calculated paced Ca2+ spark data for wt mice treated with either DMSO or TBCA. All 
results collected from C57 mice (n = 2), and isolated cells were perfused for 4 minutes with either, 1 
mM DMSO (n = 3), TBCA(100) (n = 5), or TBCA(500) (n = 5)  (A) Representative Ca2+ spark image taken 
from 500 nM TBCA treated cell in Sparkmaster with stimulated Ca2+ transients and sparks (B) Example 
data output from spark master (C) Spark frequency (D) Amplitude. (E) FWHM. Results are shown 
normalised to baseline (KRH) unpaced period and are presented as mean ± SEM. Analysis was 
performed using a one-way ANOVA with Dunnett's post hoc test. ΔF/Fo: Transient amplitude, DSMO: 
Dimethyl sulfoxide, FWHM: Full-width half max, TBCA: Tetrabromocinnamic acid, TBCA100: TBCA 
100 nM, TBCA500: TBCA 500 nM. 
 Ca2+ sparks in un-paced periods 
Following the 1 Hz paced period, external stimulation was removed to measure Ca2+ sparks in 
unpaced conditions. Figure 3.4 shows the Ca2+ spark parameters seen in an un-paced line-scan 






























































































































Similar to the case in paced conditions, DMSO-treated cells exhibited fewer Ca2+ sparks when 
compared with baseline (0.2668 ± 0.17 fold-change); both the TBCA100-treated (2.155 ± 0.88 
fold-change) and TBCA500-treated cells appeared to trend toward increased spark frequencies 
(1.805 ± 0.95 fold-change) compared with baseline. There were no statistically significant 
differences between DMSO- and TBCA100-treated cells (p = 0.47) or between DMSO- and 
TBCA500-treated cells (p = 0.51). As seen in paced periods, spark amplitude remained relatively 
consistent across all groups, with no significant changes from baseline levels seen in DMSO-
treated (0.9021 ± 0.04 fold-change), TBCA100-treated (0.8280 ± 0.76 fold-change) and 
TBCA500-treated (0.8592 ± 0.097 fold-change) cells, and no statistically significant differences 
between groups. 
Finally, whilst FWHM appeared to increase from baseline in both DMSO-treated (1.187 ± 0.26 
fold-change) and TBCA100-treated cells (2.031 ± 0.56 fold-change), it decreased in TBCA100-
treated cells (0.8865 ± 0.32 fold-change). Notably, there were no statistically significant 
differences in FWHM between the treatment groups.  
Overall, very few Ca2+ waves were seen in the analysis data set, with only one wave recorded 
during perfusion of the TBCA500 group, as seen in Figure 3.4A.  As such, this data was unable 
to be analysed. However, as Ca2+ waves represent a clear translation of increased spark events 
into cell-wide triggered arrhythmia (Lanner et al., 2010), it does suggest the presence of 
increased levels of Ca2+ cycling dysfunction in the TBCA500-treated group. This represents an 







Figure 3.4. Calculated un-paced Ca2+ spark data for wt mice treated with either DMSO/TBCA. 
All results collected from C57 mice (n = 2), and isolated cells were perfused for 4 minutes with either, 
1 mM DMSO (n = 3), 100 nM TBCA (n = 5), or 500 nM TBCA (n = 5) (A) Representative Ca2+ spark 
image taken from 500 nM TBCA treated cell in Sparkmaster with Ca2+ sparks and wave (B) Spark 
frequency (C) Amplitude and (D) Full-width half max (FWHM). Results are shown were normalised to 
baseline (KRH) un-paced period and are presented as mean ± SEM. Analysis was performed using a 
one-way ANOVA with Dunnett’s post hoc test. ΔF/Fo: Transient amplitude, DSMO: Dimethyl 
sulfoxide, FWHM: Full-width half max, TBCA: Tetrabromocinnamic acid, TBCA100: TBCA 100 nM, 
TBCA500: TBCA 500 nM. 
3.3. The impact of S2692/93 inhibition on RyR2 function and SOICR using 
a transgenic mouse model   
Pharmacological inhibition of CK2 appeared to result in a trend towards an increased SOICR 
propensity within C57 cardiomyocytes. To determine whether this was due to a specific loss of 
phosphorylation of RyR2 at S2692/93 or to loss of the total CK2 kinase itself, the effect of CK2 
inhibition was quantified using a KI-S2692/93A+/- mouse model. This analysis was conducted 
both at an in vitro level with confocal analysis of individual cardiomyocytes and Ca2+ cycling, 
as well as in vivo using Echo and ECG to assess functional and electrical changes within the 


































































































































3.3.1. Confocal microscopy in S2692/93A+/- mice 
Using a similar protocol to that used for the TBCA-treated cells, confocal microscopy was used 
to assess changes in Ca2+ cycling within individual cardiomyocytes, as well as measurement of 
Ca2+ sparks and waves to determine whether loss of phosphorylation at the previously identified 
S2692/93 residues causes an increased prevalence of SOICR events and Ca2+ cycling 
dysfunction in the S2692/93A+/- mouse. Mouse hearts were mounted on the Langendorff 
apparatus and single ventricular myocytes were isolated with collagenase type II and the 
protease method described previously (Section 2.5). Isolated cells were loaded with Ca2+ 
sensitive fluorophore (Fluo-4 AM) and perfused with varying levels of KRH-Ca2+ to imitate 
different levels of SR Ca2+ loading. Confocal LS’ were taken in either paced, or un-paced 
conditions to analyse changes in Ca2+ cycling at the cellular level.  
 Ca2+ transient data  
Two main parameters were recorded from isolated cardiomyocytes to measure RyR2 release 
under-stimulated (CICR) in vitro conditions: cytosolic Ca2+ transient amplitude (ΔF/Fo) and 
time to peak transient fluorescence (ms). The only significant difference found between the wt 
and S2692/93A+/- groups at 1.8 mM KRH-Ca2+ was in the amplitude of the Ca2+ transient seen 
at 1 Hz pacing (Figure 3.5B.), which was significantly lower in wt cells than in S2692/93A+/- 
cells (0.438 ± 0.062 vs 1.047 ± 0.082 ms; p = 0.014). 
At 3 mM and 5 mM KRH-Ca2+, there was no significant difference between wt and 
S2692/93A+/- cells in either amplitude (Figure 3.5C-D.) or time to peak transient fluorescence 
(Figure 3.5F-G.). However, at 5 mM there was a trend towards an increase in the time to peak 
(Figure 3.5G.) for S2692/93A+/- cells stimulated at 5 Hz, when compared with wt cells (p = 
0.22). Overall, these data suggest that S2692/93A+/- animals could have a slower Ca2+ release 






   
   
 
Figure 3.5. ΔF/Fo pacing and time to peak data for wt and S2692/93A+/- mice. Cells (n = 36) were 
isolated from wt (n = 2) and S2692/93A+/- (n = 4) mice (A) Exemplar trace showing 3 Hz paced wt 
myocyte, S = stimulation. Transient amplitude (ΔF/Fo) for (B) 1.8 mM KRH-Ca2+ perfused wt (n = 6) 
and S2692/93A+/- (n = 5), (C) 3 mM KRH-Ca2+ perfused wt (n = 7) and S2692/93A+/- (n = 6), and (D) 
5 mM KRH-Ca2+ perfused wt (n = 7) and S2692/93A+/- (n = 5) myocytes. Time to peak transient 
amplitude for (E) 1.8 mM perfused, (F) 3 mM perfused, and (G) 5 mM perfused wt and S2692/93A+/- 
cardiomyocytes. Results are shown as mean ± SEM. *p < 0.05. Analysis was performed using a two-
way ANOVA with Sidaks post hoc test or mixed-effects analysis (if missing values) with Sidaks post 
hoc test. wt: Wild-Type mouse, ΔF/FO: transient amplitude, KRH: Krebbs-Ringer bicarbonate buffer.  
 Ca2+ spark data 
After Ca2+ transient changes had been analysed, the next step was to conduct a Ca2+ spark 
analysis to measure the frequency and severity of sparks within isolated cardiomyocytes. As 
Ca2+ sparks represent a form of SOICR event, this can indicate an increased propensity for 
DADs and triggered arrhythmia. Spark data were collected from cardiomyocytes isolated from 
















































































































wt (n = 2) and S2692/93A+/- (n = 4) animals during the pacing periods under varying 
concentrations of perfusing KRH-Ca2+ to mimic differential SR Ca2+ loads (Figure 3.6A-J.).  
At 1.8 mM KRH-Ca2+ (Figure 3.6B, E, H.), a trend was seen among the S2692/93A+/- cells 
towards increased spark frequency at all levels of stimulation (Figure 3.6B.) compared to wt 
control cells. At 1 Hz stimulation, there was a trend towards increased spark frequency within 
cardiomyocytes isolated from the S2692/93A+/- animals compared with those from their wt 
counterparts, but this was not significant (p = 0.086). However, at 3 Hz there was a significant 
increase in spark frequency in the S2692/93A+/- cells compared with wt cells (0.082 ± 0.027 vs 
0.003 ± 0.003 Sparks/100 µm/s-1; p = 0.01). A similar trend was seen at 5 Hz, with S2692/93A+/- 
cells exhibiting increased spark frequency compared to wt (0.0959 ± 0.021 Sparks/100 µm/s-1 
vs 0.032 ± 0.021 Sparks/100 µm/s-1; p = 0.043). For those cells that expressed sparks at 1.8 mM 
KRH-Ca2+, there was no significant difference between groups with regard to either 
amplitude(Figure 3.6E.), or FWHM (Figure 3.6H.).  
For cells perfused with 3 mM KRH-Ca2+ (Figure 3.6C, F, I.), there was no significant 
difference in spark frequency (Figure 3.6C.) at 1 Hz stimulation; however, at 3-Hz stimulation, 
there was a trend towards increased spark frequency in the S2692/93A+/- cells compared with 
their wt counterparts (p = 0.2). At 5-Hz stimulation, there was a significant increase in spark 
frequency in the S2692/93A+/- cells compared with wt cells (0.076 ± 0.024 vs 0.012 ± 0.027 
Sparks/100 µm/s-1; p = 0.029). Again, among those cells that expressed sparks at 3 mM KRH-
Ca2+, there was no significant difference between groups with regard to either amplitude 
(Figure 3.6F.), or FWHM (Figure 3.6I.).  
At 5 mM KRH-Ca2+ (Figure 3.6D, G, J.), there were no significant differences in spark number 
(Figure 3.6D.), amplitude (Figure 3.6G.) or FWHM (Figure 3.6J.) between S2692/93A+/- and 




frequencies of 1 Hz (p = 0.21) and 5 Hz (p = 0.16) in S2692/93A+/- cells when compared with 
wt cells.  
Overall, these results suggest that S2692/93A+/- cells display an increased frequency of Ca2+ 
sparks compared with wt cells at lower levels of KRH-Ca2+. However, at higher levels of KRH-
Ca2+, spark frequency appeared to be similar between S2692/93A+/- and wt cells, suggesting 
that SR content was raised to such a level that even wt cells were exhibiting Ca2+ sparks. As 
Ca2+ sparks represent a form of SOICR event, this suggests an increased potential risk for DADs 






    
  
  
Figure 3.6. Summary of the characteristics of Ca2+ sparks in intact isolated cardiomyocytes during 
perfusion.  Cells (n = 36) were collected from wt (n = 2) and S2692/93A+/- (n = 4) mice. (A) 
Representative line scan (LS) from 1 Hz paced S2692/93A+/- cardiomyocyte (B – D) spark frequency 
(E – G) Spark amplitude and (H – J) Full width half maximum (FWHM) for 1.8 mM, 3 mM and 5 mM 
perfused cells during a 10-second LS. 6 wt cells and 5 S2692/93A+/- cells were perfused with 1.8 mM 
KRH-Ca2+, 7 wt and 6 S2692/93A+/- cells were perfused with 3 mM KRH-Ca2+, and 9 wt and 5 
S2692/93A+/- cells were perfused with 5 mM KRH-Ca2+. Results are presented as mean ± SEM. *p < 
0.05, **p < 0.01. Analysis was performed using a two-way ANOVA with Sidak’s post hoc test. Amp: 









































































































































































































3.3.2. S2692/93A+/- mice did not display significant morphological changes 
compared with their wt littermates  
Given the finding that frequency of SOICR events was increased in cardiomyocytes from 
S2692/93A+/- exhibited compared with those from their wt littermates, the next objective was 
to determine whether this cellular-level dysfunction translated into an increased arrhythmic 
susceptibility at the multi-system level. However, it was first necessary to confirm that the 
S2692/93A+/- KI condition was not associated with significant morphological changes such as 
hypertrophy or apoptosis. Therefore, structural measurements were recorded from each mouse 
post mortem, including HW, KW and BW. The data presented in Table 3.1. demonstrate that 
the age and BW of the animals (listed according to gender and genotype) used in this study 
were not significantly different (p>0.05) between groups. 
Table 3.1. Physical characteristics of experimental mice 
Parameter S2692/93A
+/- 
Male wt Male 
S2692/93A+/- 
female wt female 
n 6 2 2 3 
Age (weeks) 10.29 ± 1.29 9.71 ± 0.38 9.79 ± 0.07 9.81 ± 0.89 
Body weight 
(g) 20.53 ± 3.2 25.97 ± 1.434 18.85 ± 0.05 23.23 ± 2.11 
Results are expressed as mean ± SEM and were statistically analysed using two-way ANOVA (Sidaks 
post hoc test). wt: wild-type. No statistical significance was seen.  
There were no significant differences in BW (Figure 3.7A.) between male S2692/93A+/- and 
wt mice (25.97 ± 1.43 vs 20.2 ± 3.2 g; p = 0.14) or between female S2692/93A+/- (g) and wt 
mice (18.85 ± 0.05 vs 23.23 ± 2.1 g; p = 0.36). Similarly, there were no significant differences 
HW (Figure 3.7B.) according to gender between S2692/93A+/- and wt mice (male: 242.5 ± 30.9 
vs 191.5 ± 23.5 mg, p = 0.53; female: 147.5 ± 14.5 vs 191 ± 9.5 mg, p = 0.68). Although there 
was no significant difference between the KW (Figure 3.7C.) of S2692/93A+/- and wt females 
(131 ± 6.6 vs 151 ± 10.9 mg, p = 0.48), a significant increase in KW was observed between 
S2692/93A+/-  and wt males (217 ± 10.1 vs 160.4 ± 7.1 mg, p = 0.0048) males. However, when 




It is believed that the fluctuations in BW that occur with ageing render this parameter an 
unreliable reference for normalizing to HW (Yin, Spurgeon, Rakusan, Weisfeldt, & Lakatta, 
1982). Therefore, the HW of each mouse was compared against its tibial length (TL), allowing 
quantification of any possible cardiac hypertrophy within the two groups. As seen in Figure 
3.7D., S2692/93A+/- males exhibited a similar HW/TL ratio to wt males (11.6 ± 1.67 vs 8.19 ± 
0.81, p = 0.38). Similarly, female S2692/93A+/- and female wt mice were highly comparable 
(9.54 ± 0.70 vs 9.543 ± 0.28, p = >0.999), with no significant difference between any of the 
groups. These findings indicate that the S2692/93A+/- mutation did not result in extensive 
cardiac morphological changes.  
  
        
Figure 3.7. Morphological data from both S2692/93A+/-, and wt controls. Animals were stratified 
based on sex (S2692/93A+/- males n = 6, wt males n = 2, S2692/93A+/- females n = 2, wt females n = 3). 
(A) Heart weight, (B) kidney weight, and (C) body weight. (D) Heart weight normalised to tibial length 
(E) Kidney weight normalised to body weight. Results are shown as mean ± SEM. **p< 0.01. Analysis 




































































































































3.3.3. In vivo Echo findings did not differ between wt and S2692/93A+/- mice 
Having shown that wt and S2692/93A+/- mice were overall morphologically similar, and that 
alteration of these sites did not markedly increase mortality or disability, it was vital to 
determine any in vivo functional changes. Therefore Echo analysis was performed using the 
protocol described in Chapter two, Section 2.4.5.  Echo data from S2692/93A+/- and wt mice 
were collected at baseline and at 2, 5, 15, 30, 45 and 60 minutes after acute pharmacological 
(adrenaline/caffeine) stress (Figure 3.8.). Key cardiac parameters considered included FS, 
EDV, EF, ESV, SV, CO, HR, R-R interval, and ΔHR. A full account of all parameters measured 
is given in Appendix 2, Figure 0.1.  including IVSd, IVSs, LVIDd, LVIDs, LVPWd and 
LVPWs. Additionally, a full list of analysed parameters with mean ± SEM at each time period is 
detailed in Appendix 2, Table 0.6. At baseline, there was no significant difference between wt 
and S2692/93A+/- mice ( 
Table 3.2) regarding any of the analysed Echo parameters. 
Table 3.2. Key cardiac parameters at baseline. 
Parameter Wild-type S2692/93A+/- p 
FS (%) 42.4 ± 4.4 43.1 ± 2.54 > 0.999 
EF (%) 78.7 ± 4.64 79.2 ± 2.52 > 0.999 
EDV (mL) 0.0638 ± 0.0107 0.0901 ± 0.00867 0.485 
ESV (mL) 0.015 ± 0.00472 0.019 ± 0.00307 0.993 
SV (mL) 0.0488 ± 0.00697 0.0724 ± 0.00616 0.199 
CO (L/min) 0.0158 ± 0.0022 0.0262 ± 0.00302 0.121 
HR (BPM) 331 ± 23.3 359 ± 18.9 0.961 
CO: cardiac output, EDV: end-diastolic volume, EF: ejection fraction, ESV: end-systolic volume, FS: 
fractional shortening, HR: heart rate, SV: stroke volume,  
There was an initial decrease in FS from baseline in both wt and S2692/93A+/- animals (Figure 
3.8A.), generally reaching its lowest point at around 5 minutes post-stress in both S2692/93A+/- 




minutes post-stress. There were no significant differences in FS measurements between wt and 
S2692/93A+/- animals at any time point. EDV (Figure 3.8C.) and ESV (Figure 3.8D.) values 
at baseline and throughout the stress response were generally comparable between 
S2692/93A+/- mice and wt controls. In S2692/93A+/- mice, EDV and ESV peaked at 15 minutes 
post-stress before both returning to baseline levels by 60 minutes post-stress. Peak levels of 
EDV and ESV were 0.129 ± 0.024 mL and 0.054 ± 0.012 mL, respectively; these data for wt 
animals were 0.065 ± 0.012 ml and 0.027 ± 0.008 mL, respectively. Again, there were no 
significant differences in ESV or EDV measurements between wt and S2692/93A+/- animals at 
any time point. 
EF (Figure 3.8E.) decreased following the stress test, before eventually returning to around 
baseline levels. Although S2692/93A+/- animals did appear to exhibit a trend towards lower EF 
in the later stages of the stress response, the difference relative to wt littermates was not 
significant. SV appeared to be higher in S2692/93A+/- animals compared with their wt 
counterparts, with a trend seen at 5 minutes post-stress between S2692/93A+/- and wt animals 
(0.078 ± 0.01 vs 0.038 ± 0.007 mL, p = 0.0514) groups. However, no significant differences 
were seen between the two groups at any time point. HR (Figure 3.8G.) predictably increased 
immediately from baseline in both groups following the stress response (wt: 330 ± 23 beats per 
minute [BPM]; S2692/93A+/-: 359 ± 19 BPM), generally peaking at around 2 minutes post-
stress (wt: 389 ± 21 BPM; S2692/93A+/-: 419 ± 21 BPM) before returning to around baseline 
levels by around 15 minutes post-stress (S2692/93A+/-: 339 ± 34 BPM; wt: 343 ± 16 BPM). As 
expected, this increase in HR was accompanied by a decrease in the R-R interval (Figure 
3.8H.), which also slowly returned to baseline levels. Neither HR nor R-R interval was 
significantly different between wt and S2692/93A+/- animals at any time point. 
Changes in CO matched those in HR (Figure 3.8F.), with the stress response eliciting a minor 




differences were seen between the groups. HR change from baseline (Figure 3.8I.) was also 
calculated. Notably, there was a large degree of variability within the S2692/93A+/- group, with 
some animals either exhibiting no change in their HR or even demonstrating decreased HR in 
response to the acute stress test. This was reflected in the large SEM seen in the S2692/93A+/- 
5-minute group (0.886 ± 0.199 fold-change from baseline) when compared with the wt control 
animals (1.19 ± 0.054 fold-change from baseline); however, the difference was not significant 
(p > 0.05). 
These results suggest that overall, the functional characteristics at baseline, and in response to 
an acute pharmacological stressor were comparable between S2692/93A+/- and wt mice, 
indicating that the mutation had not significantly altered the functional characteristics of the 







Figure 3.8. Echocardiographic data in RyR2 wt and S2692/93A+/- mice. (A) Fractional shortening 
(FS). (B) End-diastolic volume (EDV). (C) Ejection fraction (EF). (D) End-Systolic volume (ESV). (E) 
Stroke Volume (SV). (F) Cardiac Output (CO). (G) Heart Rate (HR). (H) R-R interval. (I) Change in 
HR from baseline (calculated as Baseline HR ÷ calculated HR). Results were obtained from 13 
independent experiments where, wt control (n = 5), and S2692/93A+/- (n = 8) mice were subjected to a 
pharmacological stress test, and echocardiographic measurements were taken at baseline (0), and at 2, 
5, 15, 30, 45, and 60 minutes post-stress. Results are shown as mean ± SEM. Analysis was performed 
using a mixed-effect model with Sidaks post hoc test.     
3.3.4. In vivo ECG analysis of wt and S2692/93A+/- mice 
The greater levels of Ca2+ cycling dysfunction and SOICR propensity observed in S2692/93A+/- 
cells compared with wt cells may translate into an increased propensity for arrhythmic activity 
in vivo. ECG was used to determine both the susceptibility to and severity of the arrhythmias 
exhibited by these two groups of mice. A lead II, two-lead ECG was performed on anaesthetised 
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mice using the protocol described in Chapter Two, Section 2.4.4. Post-experiment, this trace 
was then analysed in 1-minute bins to identify beats considered to be in non-sinus rhythm 
(NSR) for each animal. The number of non-sinus beats was then divided by the total HR for 
that minute, giving a percentage value for time spent in arrhythmia over that period. This 
process was repeated in each of the groups over 65 minutes, with five baseline readings and 60 
post-stress readings being recorded to provide a comprehensive baseline and post-stress 
response.  It was hypothesised that S2692/93A+/- mice would display an increased susceptibility 
for arrhythmia when compared with wt mice, and that this would manifest in a higher 
percentage time in NSR.   
The most common form of arrhythmia observed was self-terminating bigeminy (Figure 3.9A.), 
a form of ectopic beat that results in biphasic rhythms, one long and one shorter. However, 
other forms of arrhythmia were seen: PVCs (including EADs, and DADs) (Figure 3.9B.), non-
sustained ventricular fibrillation (Figure 3.9C.) and monomorphic and bi-morphic ventricular 
tachycardia (VT) (Figure 3.9D.). Throughout this analysis, however, there was no significant 
difference in percentage NSR between the S2692/93A+/- and wt animals at any time point 
(Figure 3.10.).  
Figure 3.10. represents the percentage time spent in NSR for both wt and S2692/93A+/- mice 
over the 65-minute analysis window. In the 5 minute baseline period, neither wt nor 
S2692/93A+/- mice expressed any form of NSR events. However, almost immediately following 
administration of the stress test, the number of NSR events rose in both groups peaking at 
around 3–8 minutes post-stress, which was followed by a reduction in the level of NSR events. 
There was a large degree of inherent variability within both groups; with some animals 
exhibiting sustained arrhythmia for the entire 60 minutes, while others expressed almost no 




difference between S2692/93A+/- and wt mice at any point during the post-stress response, 
suggesting that there was no difference in the arrhythmic susceptibility between the two groups.  
 
Figure 3.9. Examples of arrhythmic events within murine lead II ECG trace. (A) Sustained 
bigeminy (B) example of premature ventricular contractions (PVCs) (early after depolarisations and 
delayed after depolarisations) and monomorphic ventricular tachycardia (C) Un-sustained period of 
Ventricular tachycardia (VT) / Ventricular fibrillation (VF). (D) Sustained bi-directional VT.* denotes 
a non-sinus rhythm event. All traces are taken from S2692/93A+/- animals.  
 
Figure 3.10. Percentage time spent in NSR of wt and S2692/93A+/- mice. Determined from post-
stress (ST) (60-minute duration) response to acute intraperitoneal injection of adrenaline (1.6 mg/kg) 
and caffeine (120 mg/kg). Results are expressed as mean ± SEM. Data were collected from wild-type 
(n = 5) and S2692/93A+/- (n = 8) mice. Statistical analysis was performed using two-way ANOVA. No 
statistical significance was achieved when comparing wt and S2692/93A+/- groups. ST: stress test, NSR: 
Non-sinus rhythm, wt: Wild-type mouse. 
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 Arrhythmia scoring results 
An adapted arrhythmia scoring method (Curtis & walker, 1988) (see Section 2.4.6.1) was used 
to quantify the acute stress response of both wt and S2692/93A+/- mice. Figure 3.11. depicts 
the non-normalised arrhythmia scoring over the entire 60-minute period in the ECG trace of 
both groups. In the S2692/93A+/- group, the arrhythmia mean score (scored on a scale of 0–5, 
with 5 being the most severely arrhythmic) was 2.11 ± 0.46, while in the wt group the mean 
score was 2.8 ± 0.49; consistent with the analysis at the per-minute level, no statistical 
significance was identified upon comparison between the two groups. These data suggest, 
unexpectedly, that there was no difference between the S2692/93A+/- and wt animals with 
regard to identified arrhythmic events in response to the stress test.  
 
 
Figure 3.11. Arrhythmogenic susceptibility of S2692/93A+/- mice. Arrhythmia score is given for post-
stress (60-minute duration) response to acute intraperitoneal injection of adrenaline (1.6 mg/kg) and 
caffeine (120 mg/kg). The original scoring system of Curtis and Walker (1988) that rates arrhythmic 
severity and duration on a numerical scale of 1–5 (5 being most severe arrhythmic profile) was adapted 
for this study. Results are expressed as mean ± SEM. Data were collected from wt (n = 5) and 
S2692/93A+/- (n = 8) mice. Statistical analysis was performed using uncorrected 2-tailed unpaired t-test. 

































In this project, adverse cardiomyocyte Ca2+ cycling was investigated, and the role of PTMs of 
RyR2 in cardiac dysfunction and disease. RyR2 is a sarcoplasmic reticulum localised Ca2+ 
channel found in cardiomyocytes (Bers, 2002b), with a large cytosolic domain accessible for 
modification. Previous literature has highlighted the role of numerous PTMs on the regulation 
of the RyR2 channel, and in particular oxidation (Meissner, 2004; Waddell et al., 2016) and 
phosphorylation (Dobrev & Wehrens, 2010; Valdivia, 2012), which have been shown to 
increase SOICR events by reducing the RyR2 luminal Ca2+ threshold for SOICR (Jones et al., 
2017; Waddell et al., 2016). However, the sheer size of the channel alone means there is still 
inadequate knowledge regarding the role of many specific RyR2 modification sites, and the 
role they might play in cardiac dysfunction.  
There is currently limited knowledge regarding the role of CK2 in RyR2 dysfunction and 
arrhythmia, and understanding this relationship is crucial to the development of novel and 
targeted treatments for patients. Preliminary research within the Jones lab (unpublished data) 
has revealed that in both human right atrial appendage and LV tissue samples, patients with 
HFrEF exhibit a reduced level of phosphorylation at S2692/93. This is significant, as cardiac 
disease represents the leading cause of mortality worldwide (Fuster, 2014; Health, 2015a);  
>50% of CVD-related deaths can be attributed to sudden cardiac death (Myerburg, Kessler, & 
Castellanos, 1993; Zipes et al., 2006), the leading causes of which are ventricular arrhythmias 
and HF (Mukharji et al., 1984). There is a clear need within the health sector for novel 
treatments to address this growing health epidemic and improve existing treatments.  The aim 
of the present research was thus to explore the role of RyR2 in health and disease, focusing on 
the role phosphorylation might play in modulating RyR2 function. 
The first goal of this study was to examine the ability of RyR2 to be dynamically regulated by 




S2692/93 was examined within ZDF diabetic rats using Western blotting. The second objective 
was to determine the effect of a chronic loss of CK2 phosphorylation at RyR2 sites S2692/93 
both in vitro via a pharmacological inhibition study, and in vivo using a transgenic mouse model 
in which RyR2 phosphorylation by CK2 is inhibited (S2692/93A+/-). This analysis was 
conducted using in vivo (Echo and ECG) and ex vivo (confocal microscopy) measures. Overall, 
these findings demonstrate that while loss of CK2 phosphorylation resulted in increased SOICR 
events at the cellular level, this did not translate to multi-system–level arrhythmia or cardiac 
dysfunction.  
4.1. Likely mechanistic action of CK2 on RyR2 
As evidenced by the present findings, there appears to be a relationship between loss of CK2-
associated phosphorylation at RyR2 and increased propensity for SOICR events at the cellular 
level. Given this identification of a clear relationship between CK2 and RyR2, the question 
remains: how does CK2 impose these changes upon RyR2? The work of Peng et al. (2016) and 
their cryo-electron microscopy structure of the RyR2 channel down to the near-atomic 
resolution level (4.2Å) has been invaluable towards developing a theory to explain how a single 
phosphorylation residue can alter RyR2 channel function. Allowing identification of single 
amino acid sequences within the three-dimensional structure of the channel allows visualisation 
of the S2692/93 sites, and therefore theoretical discussion around the likely mechanism of 
action of CK2. Previous work by Chakraborty (2018) has already provided in-depth analyses 
of these sites and the putative mechanism of action of CK2 on RyR2; the findings of the present 
study support those analyses. 
The main conformational movement of the channel is coordinated by the shifts in the handle 
and helical domains (Figure 4.1.), from which relative shifts translate into larger 
conformational changes of the cytoplasmic domains to allow channel gating (Peng et al., 2016). 




found within the wider helical domains 1/2 (HD1/HD2). The helical domain is located on the 
cytosolic aspect, which makes up about 80% of the channel and has already been identified as 
displaying large conformational movements during activation (Wei et al., 2016). This area is 
hardly novel with regard to phosphorylation residues, with other key phosphorylation sites at 
S2808 and S2814 also being located within this domain. Importantly, for this site to be acted 
upon by a kinase, it must be accessible; looking at the schematic shown in Figure 4.2. suggests 
that the S2692/93 region is located close to the exposed surface of the channel, which is critical 
in ensuring the docking of CK2.  
The presence of phosphorylation at residues S2692/93 might stabilise the channel, as it reduces 
its activity. It is my belief that the addition of the phosphorylation group to these domains results 
in the creation of novel electrostatic residues, due to the negative charge associated with the 
addition of the phosphorylation group. This may prevent the conformational change associated 
with the helical and P2 domains, leading to a reduction in their interaction with the channel 
domain and resulting in decreased activity and channel conductance in the overall RyR2 
channel.  
 
Figure 4.1. Schematic representation of RyR2 monomer domain. The likely location of S2692/93 is 
within the P2 domain (blue box), which itself is located between the two helical domains (HD1/HD2). 
This P2 domain also contains a number of well-characterised phosphorylation sites; such as S2808, and 
S2814. Taken from Peng et al. (2016). NTD: N-terminal domain, SPRY1/2/3: SPla and the RYanodine 









Figure 4.2. Mapping of the S2692/93 sites within the RyR2 tetramer. Magnified view of the P2 and 
helical domains (HD1/HD2) from one of the RyR2 monomers. The red dot represents the general 
location (S2700) of S2692/93 within the RyR2 monomer, as the exact location is not yet resolvable from 
current structures. Taken from Chakraborty (2018). 
4.2. Assessing the ability of RyR2 to be dynamically modified in vitro 
4.2.1. Changes in S2692/93 phosphorylation do not occur in ZDF diabetic rats  
Diabetic heart disease has been characterised by altered RyR2 function leading to increased 
Ca2+ leak (Belke, Swanson, & Dillmann, 2004; Pereira et al., 2006; Zhao et al., 2006). As such, 
it was initially hypothesised that in DM a reduction in CK2, and by extension phosphorylation 
at S2692/93 would be observed. Within the ZDF diabetic rat line (Figure 3.1.), Western 
blotting clearly showed high levels of basal phosphorylation of RyR2 in both DM and N-DM 
conditions, supporting the conclusion that CK2 is constitutively active (Bosc et al., 2000), and 
phosphorylating these sites. However, densitometric analysis revealed no significant difference 
between the DM and N-DM groups regarding S2692/93 phosphorylation levels (phospho 
antibody staining normalised to total tissue RyR2 expression identified using 34C antibody 
staining); this was a surprising, and unexpected result. It could be that the high levels of 
phospho-RyR2 in basal conditions means gauging reduced phosphorylation using only a 




blotting methods have been used with human tissue samples (Jones lab, unpublished data) and 
showed that phosphorylation of these sites is decreased in HFrEF (Figure 4.3.), and these 
studies formed the basis for ongoing investigation at these sites. 
 
Figure 4.3. Densitometric analysis of Western blot of protein extracted (left) human right atrial 
appendage and (right) human LV tissue. Both antibodies 616 and 619 are phospho-S2692/93 
antibodies. All results are shown as mean ± SEM. *p < 0.05. Statistical analysis was performed using 
two-tailed unpaired t-test. Jones lab (unpublished). Preserved EF: HF with preserved EF, reduced: HF 
with reduced EF. 
4.3. Assessing the impact of a loss of CK2 on RyR2 function 
4.3.1. Impact of pharmacological inhibition of CK2 on the propensity of, 
and release threshold for SOICR. 
Pharmacological inhibition of CK2 using the CK2-specific blocker TBCA was conducted in an 
in vitro cell model to investigate the impact of loss of S2692/93 phosphorylation on SOICR. 
TBCA is regarded as an optimal CK2-blocking compound due to its high specificity and low 
off-target effects compared with other CK2 inhibitors (Brown et al., 2018; Pagano et al., 2007). 
Ensuring a potent inhibition of CK2 is vital, as other studies have shown that even a 95% loss 
of CK2 produced only a 50% decrease in its phosphorylation levels (McFarland et al., 2011). 
This demonstrated not only CK2s specificity, but also the need for a complete block to 
determine any association between its loss and altered Ca2+ cycling.  As suggested by the 
present results, acute pharmacological inhibition of CK2 caused a trend towards increased 



































































































paced (Figure 3.4.) conditions. Furthermore, TBCA-treated cells trended towards a longer time 
to Ca2+ transient peak (Figure 3.2.), implying that even extremely acute inhibition of CK2 in 
cardiomyocytes could increase the time taken for Ca2+ cycling and release to occur.   
Taken together, these results suggest that acute pharmacological inhibition of CK2 in vitro 
reduces phosphorylation of the P2 domain, leading to reduced electrostatic activity within the 
RyR2 channel. This, in turn, would increase the interaction between P2 and the channel domain 
and result in a reduced luminal Ca2+ threshold and increased channel conductance and therefore 
higher levels of SOICR events, which could increase the risk of DADs and arrhythmia.  
These conclusions are limited by the lack of significant results, as this data is still in its very 
preliminary stages, with particularly low n values hindering the statistical analysis. The drug 
concentrations used should also be considered; previous studies have used concentrations as 
low as 100 nM TBCA and seen an effect (McFarland et al., 2011), but this was within cultured 
cell lines treated for 48 hours. Comparatively, the method implemented in the present study 
utilised a live cell imaging model using confocal microscopy, with cell quality degrading 
rapidly following mortality. Other studies have shown that TBCA can be used in cardiac-
associated cells in doses as high as 5 µM without effecting cell apoptosis (Brown et al., 2018), 
and altering the TBCA concentrations might help elucidate further conclusions from this data.  
4.4. S2692/93A+/- mutant KI mice 
4.4.1. RyR2 S2692/93A+/- mice display no severe defects in whole-body 
morphology 
In vitro pharmacological inhibition of CK2 appeared to cause a trend towards increased SOICR 
propensity. To determine whether this was the result of a specific loss of phosphorylation of 
RyR2 at S2692/93 or simply due to loss of the CK2 itself, the effect of CK2 inhibition was 
quantified using a genetic S2692/93A+/- KI-mouse model. First, as CK2 dysfunction has been 
implicated in several types of tumorigenesis (Hauck et al., 2008), cell proliferation (Xiaohua 




pre-experimental analysis of whole-body morphology was crucial to ensure this genetic KI had 
not caused any gross morphological changes within the S2692/93A+/- mouse model. Most 
studies have shown that these pathways are specific to CK2 modification, and only occur with 
its overexpression (Murtaza et al., 2008). As such, it was hypothesised that as only the ability 
of CK2 to act on RyR2 (at S2692/93) was diminished, the prevalence and activity of CK2 
should remain unchanged. As expected, the results (Figure 3.7A-E.) demonstrated no 
abnormality within the S2692/93A+/- animals compared with their wt littermates, and while 
KW was observed to be significantly higher in S2692/93A+/- males compared to wt males, this 
trend was not significant when adjusted for BW. Overall, these results indicate that within the 
parameters examined, it did not appear that the genetic KI led to significant changes in whole-
body morphology. 
4.4.2. S2692/93A+/- cardiomyocytes displayed higher levels of SOICR events 
Following the promising findings of the pharmacological inhibition study, the level of SOICR 
events occurring within S2692/93A+/- cardiomyocytes was quantified using an in vitro analysis. 
Perhaps the most exciting result within this project is that for the first time within a live 
cardiomyocyte cell model, a loss of CK2 associated phosphorylation of RyR2 appears to lead 
to increased Ca2+ sparks, a form of SOICR event (Figure 3.6B-D.), without affecting amplitude 
or FWHM (Figure 3.6E-J.) in isolated cardiomyocytes. There was a substantive trend within 
S2692/93A+/- cells towards a greater frequency of SOICR events. This was best seen at lower 
KRH-Ca2+ levels, whereas at higher levels of KRH-Ca2+ differences in spark frequency were 
less evident. This could be due to the elevated SR Ca2+ content more readily surpassing the 
SOICR threshold in both S2692/93A+/- and wt mice at higher SR-Ca2+ content levels.  
Analysis of the paced data revealed a significant increase in the Ca2+ transient amplitude at 
lower Ca2+ levels, indicating higher levels of Ca2+ release at baseline within S2692/93A+/- cells 




S2692/93+/- RyR2 channel under CICR conditions. This increased Ca2+ release during CICR 
would result in a diminished SR Ca2+ content on a beat-to-beat basis. This is particularly 
interesting as S2692/93+/- cardiomyocytes continue to exhibit increased SOICR events 
compared with wt cardiomyocytes, suggesting that despite an overall diminished SR Ca2+ 
content, they still exhibit significantly more SOICR events than do wt cells.  
Overall, these data outline the importance of CK2 within the cardiac system, and highlight the 
clear contrast between CK2 and all previously identified kinases, in particular, CaMKII and 
PKA, which have all been functionally implicated in reducing SOICR threshold via increased 
phosphorylation in HF conditions (Wehrens and Dobrev., 2010; Valdivia., 2012; Eschenhagen., 
2010). The present results extend the growing body of evidence that suggest  the association 
between CK2 and RyR2 is cardioprotective, and that a loss of phosphorylation at this site, via 
mechanisms outlined in Section 0. lead to a loss of RyR2 channel stability and elevated risk of 
SOICR events.  
One limitation of these data was the lack of Ca2+ wave analysis, as Ca2+ waves can only be seen 
in un-paced periods, which were not included in the original confocal LS protocol. These 
periods were only introduced late in the project, with limited n values, thus preventing statistical 
analysis. Ca2+ waves represent a well-characterised arrhythmic trigger (Lakatta, 1992; D. Sato 
et al., 2014) and would have helped link the RyR2 dysfunction seen in cardiomyocytes with 
increased prevalence of arrhythmic events.  
Another issue lay in the method of data collection, in that cardiomyocytes isolated were from 
mice that had already been subjected to the pharmacological stress test and in vivo analysis. As 
such, the quality of the cells was often not sufficient for confocal analysis. Some mice had 
expressed complex arrhythmia for up to 60 minutes before excision of the heart, and had 
severely altered cardiac parameters, presenting a clear problem within what is already a 




more time, isolation from animals that had not undergone stress testing might allow greater 
yields and improved cell quality. However, it is important to note that all hearts from both wt 
and S2692/3A+/- mice had been exposed to the same experimental conditions prior to 
cardiomyocyte isolation, making differences observed during live cell imaging likely a result 
of the genotype and not pre-isolation conditions. Overall, these results indicated a higher 
number of SOICR events in S2692/93A+/- animals, suggesting that even a partial loss of CK2 
cardioprotective phosphorylation on RyR2 leads to increased diastolic Ca2+ leak, and 
potentially an increase in the risk of DADs and arrhythmias. 
4.4.3. RyR2 S2692/93A+/- mice display no severe defects in cardiac structure 
Echo provides a detailed and non-invasive method of quantifying cardiac function and 
remodelling information within an in vivo setting, and was an ideal tool for obtaining 
measurements pf cardiac function both pre- and post-stress. The Echo data demonstrated that 
at both baseline (Table 3.2.) and post-stress, the functional parameters of wt and S2692/93A+/- 
mice were comparable (Figure 3.8.). The RyR2-S2692/3A+/- mutation itself did not appear to 
induce gross changes in cardiac structure or function. Only one trend was seen, with 
S2692/93A+/- animals exhibiting a possibly higher SV immediately post-stress, suggesting a 
heightened stress-induced contractile response in S2692/93A+/- animals compared with their wt 
littermates.  
Overall, these results suggest that S2692/93A+/- animals did not display severe structural 
defects, despite the increase in SOICR events seen in S2692/93A+/- cardiomyocytes (Section 
3.3.1.2.). The comparability of these groups was not unexpected; these findings are consistent 
with previous KI-catecholaminergic polymorphic ventricular tachycardia mouse studies that 
have demonstrated increased SOICR events and diastolic Ca2+ leak at the cardiomyocyte level, 




Most studies that are based heavily on Echo data rely on consistent HRs between groups to 
improve the validity of the conclusions reached (W. Chen et al., 2014; Zhou et al., 2011). Within 
the present data set, issues with intra-animal anaesthetic tolerance did not allow HR matching 
to occur; however, the impact of this is somewhat negated by the lack of significance between 
the two groups, at least demonstrating that they were comparable at baseline. However, it must 
be acknowledged that this issue does somewhat reduce the validity of the conclusions reached 
and presents a concern for this ongoing research that must be addressed.   
4.4.4. In vivo ECG analysis 
The in vivo ECG analysis provided some of the most interesting results to arise from this 
project, as it was expected that the reduced CK2 phosphorylation of RyR2 that had increased 
SOICR events at the cellular level would manifest as arrhythmias initiated by increased SOICR 
events. This increased Ca2+ leak from RyR2 would be expected to lead to the generation of 
increased DADs and subsequently arrhythmia within the S2692/93A+/- animals (El-Armouche 
et al., 2006). Despite numerous S2692/93A+/- and wt animals displaying arrhythmia, no 
significant difference was found between groups with regard to percentage time spent in non-
sinus rhythm at any point following induction of the stress test (Figure 3.10.).  
Additionally, there were no significant differences between S2692/93A+/- and wt animals when 
the entire post-stress response was quantified using an arrhythmic scoring profile (Figure 
3.11.). This result was particularly surprising since it contrasted with similar studies showing a 
clear translation of cellular Ca2+ dysfunction into an adverse arrhythmic phenotype in vivo (Bai 
et al., 2013; W. Chen et al., 2014). This could be due to a variety of factors, including 
appropriate caffeine/adrenaline dosage, variances in anaesthetic tolerance, and intra-observer 
measurement issues. The most likely issue lies in the quantification of the data, as accurate 
ECG analysis requires trained experts and a complex understanding of the murine ECG 




measurement used within the study was inappropriate. Other studies have focused instead on 
time spent and duration of VT events (W. Chen et al., 2014) as opposed to solely non-sinus 
rhythm events. This could provide another avenue for future analysis by instead measuring the 
severity and type of arrhythmia expressed, and not solely the time spent in NSR.  
ECG  has other important limitations that should be considered, such as subjectivity. While 
blinding during the experimental and analysis phases of this project provided some basis of 
impartiality, in order to defer any substantial conclusions from this data set, as done in other 
studies (Khoo et al., 2006), multiple measurements with blinded assessors should be used to 
provide measurements into intra, and inter-observer error. Conversely, given that S2692/3A+/- 
are heterozygous, and still express a wt allele, this could be masking the effect of the KI and 
preventing the translation of cellular dysfunction into the adverse phenotype, as had been 
expected. Perhaps the best way to address this limitation would be to analyse the homozygous 
S2692/3A+/+ mouse model, which is currently being bred and was not available for this project 
due to time constraints.  
4.5. Limitations  
This research represents the first attempt to demonstrate that a loss of CK2 mediated RyR2 
phosphorylation leads to Ca2+ cycling dysfunction in vivo. As such, this project is ongoing, with 
optimisation continuing within many of the experiments mentioned. One of the major 
limitations of this study has been the relatively low availability of cells for confocal analysis. 
A reduction in the severity of the stress test, or even its attenuation may be necessary to ensure 
a consistently reproducible method for attaining healthy, high-quality cardiomyocytes.  
Furthermore, the origin of the tissues used throughout this study must be acknowledged, 
although both RyR2 (Bers, 2002b) and CK2 (Murtaza et al., 2008) are highly conserved across 
species, it cannot be assumed that their function is identical between mice and humans. There 




(Bers, 2002a), HR variability, and differences in neural control (parasympathetic dominant in 
humans vs sympathetic dominant in mice) (Milani-Nejad & Janssen, 2014). Furthermore, mice 
do not develop diabetes naturally; since the disease was induced artificially in the present study, 
it is far from a perfect model. Overall, while these species and tissue differences may be subtle, 
they must still be acknowledged. 
4.6. Clinical relevance of CK2 
Cardiac disease is a global health issue, and arrhythmic patients are at high risk of sudden 
cardiac arrest. Current treatment for arrhythmia includes β-adrenergic blockade via β-blockers, 
alongside angiotensin-converting enzyme inhibitors and diuretics (Currie et al., 2011). β-
blockade is known to reduce RyR2 activity and is protective against SOICR and associated 
arrhythmias (Zhou et al., 2011). However, while they do reduce immediate risk of 
tachyarrhythmias – the most common cause of sudden death in patients who have suffered  
myocardial infarction (Mukharji et al., 1984), this comes at the expense of an overall increase 
in long term HF risk, with some studies showing no benefit of β-blockers on overall patient 
mortality (Bangalore et al., 2014).  
Therefore, novel treatments for arrhythmia and cardiac disease are in high demand, and there 
is much room for improvement through additional treatments. Since CK2 is expressed 
ubiquitously and phosphorylates its targets to such a high basal level, new techniques may focus 
on maintaining physiological levels of CK2, as opposed to preventing hyper phosphorylation, 
as in the case of CaMKII or PKA. However, numerous pathologies have been associated with 
CK2 overexpression, such as tumorigenesis (Burton et al., 1999; Xiaohua Huang et al., 2006) 
and hypertrophic pathways (Hauck et al., 2008; J.-M. Li & Brooks, 1997; McFarland et al., 
2011). Additionally, with the wide range of cardiac targets for this enzyme, it may be difficult 
to ensure a balance between beneficial and detrimental changes, and may require a more 





4.7. Future directions 
4.7.1. Re-analysis of ECG data  
As outlined earlier, the results of the ECG data were inconclusive and possibly due to 
inadequate measurement of arrhythmic susceptibility in an in vivo context. Re-analysing these 
data with adapted protocols to account for arrhythmia severity, alongside additional blinded 
assessors might help discriminate between groups and provide a more representative data set.  
4.7.2. Analysis of homozygous S2692/93A+/+ and S2692/93D+/+ 
The generation of homozygous S2692/93A+/+ mice represents an exciting opportunity to 
examine the effects of a complete loss of CK2 mediated phosphorylation at the S2692/93 sites 
on cellular and multi-system function. This mouse model could potentially yield similar or 
enhanced cellular-level data, and perhaps without the potential attenuation associated with the 
presence of a wt allele seen in the heterozygous mice. The cellular dysfunction seen in the 
homozygous animals would translate into a mouse model with a clearer arrhythmic profile.  
Conversely, the generation of a S2692/93D+/+ mouse represents a novel method by which to 
examine continuous phosphorylation of these sites, via replacement of the S residue with 
glutamic acid (mimics phosphorylation).  This mouse is currently being bred but was not 
available for this project due to time constraints. It is expected that S2692/93D+/+ mice will 
exhibit a reduced arrhythmic susceptibility. Interestingly, however, as the present model of CK2 
function (S2692/93A+/-) confers a high basal level of RyR2 phosphorylation, it would be 
interesting to see if this model demonstrates significantly increased protection from arrhythmia 
compared with wt animals.  
4.8.  Conclusions 
This study explored the relationship between phosphorylation and changes in RyR2 function, 
looking specifically at two main sites; S2692/93. The in vitro aspect of this study revealed that 
RyR2 is extensively phosphorylated by CK2, and that unlike the previously reported findings 




aspects of this project displayed the effect of a chronic pharmacological- or genetic-mediated 
loss of CK2-mediated phosphorylation of RyR2. This study has demonstrated for the first time 
that loss of CK2 phosphorylation at S2692/93 led to an increased number of SOICR events and 
augmented diastolic Ca2+ leak at the cellular level. This, however, did not translate into whole 
animal arrhythmia as expected, suggesting a possible mitigating effect inhibiting the translation 
of cellular to organ level dysfunction. Based upon the results seen, it is reasonable to conclude 
that RyR2 is phosphorylated by CK2 at S2692/93, and this phosphorylation reduces SOICR 
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4.9. Appendix One: Western blotting solutions 
Table 0.1. Running buffer. Prepared in MilliQ-H2O. 
Ingredients  Concentration  Supplier  
Glycine  192 mM  Thermo Scientific  
Tris  25 mM  VWR Global Science  
SDS  1% (w/vol)  Thermo Scientific  
 
Table 0.2. Transfer buffer. Prepared in MilliQ-H2O 
Ingredients  Concentration  Supplier  
Glycine  192 mM  Thermo Scientific  
Tris  25 mM  VWR Global Science  
SDS  0.01% (w/vol)  Thermo Scientific  
Methanol  20% (vol/vol)  Lab Serv  
 
Table 0.3. PBST.  
Ingredients Amount (1 L) Supplier  
10x PBS 100 mL Jones Lab 
Tween-20 5 mL Thermo Scientific  
MilliQ-H2O  895 mL Jones Lab 
 
Table 0.4. BSA 5%. Prepared in PBST. 
Ingredients   Amount  Supplier  
PBS-T 50 mL Jones Lab 
BSA 2.5 g Life Technologies 
 
Table 0.5. 5% Milk. Prepared in PBS. 
Ingredients   Amount  Supplier  
PBS (34C)  40 mL Jones Lab 













4.10. Appendix Two; In vivo echocardiographic data 
 
Figure 0.1. Echocardiographic data in wt and S2692/93A+/- mutant mice. (A) Intraventricular septal 
thickness at end-diastole (IVSd) (FS) (B) Intraventricular septal thickness at end-systole (IVSs) (C) 
Left-ventricular internal dimensions in diastole (LVIDd) (D) Left ventricular internal dimensions in 
systole (LVIDs) (E) Left ventricle posterior wall thickness in diastole (LVPWd) (F) Left ventricle 
posterior wall thickness in systole (LVPWs) (G) Results were obtained from 13 independent 
experiments where, wt control (n = 5), and S2692/93A+/- (n = 8) mice were subjected to stress test, and 
echocardiographic measurements were taken at baseline (0), and 2, 5, 15, 30, 45, and 60 minutes post-
stress. Results are shown as mean ± SEM. Analysis was performed using a mixed-effect model with 
Sidaks post hoc test.  No significant differences were found between wt and S2692/93A+/- groups.  
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Table 0.6. Echocardiograph raw data. Values are presented as mean ± SEM; two-way ANOVA was 
conducted between S2692/93A+/- and wt animals at all time points and no statistical difference was recorded.  
Measurement 0 2 5 15 30 45 60 
S2692/93A+/- n  = 8 n = 6 n = 8 n = 8 n = 7 n = 6 n = 6 
FS (%) 43.1 ± 2.54 34.9 ± 2.67 33 ± 4.11 26.4 ± 2.15 30 ± 3.65 38.4 ± 5.26 39.8 ± 3.13 













EF (%) 79.2 ± 2.52 70.5 ± 3.3 66.4 ± 5.12 58.1 ± 3.48 62.6 ± 5.67 73.1 ± 6.1 76.3 ± 3.75 





















0.0939 1.42 ± 0.142 










0.123 1.84 ± 0.111 










0.223 2.81 ± 0.201 
LVIDs (mm) 1.86 ± 0.122 
2.14 ± 




0.236 2 ± 0.263 1.71 ± 0.186 










0.166 1.78 ± 0.118 








0.134 2 ± 0.161 
1.96 
±0.0917 











































wt n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 
FS (%) 42.4 ±4.4 29.7 ± 2.59 30.2 ± 3.57 29.1 ± 3.28 34.8 ± 2.35 39.1 ± 3.65 43.8 ± 4.19 













EF (%) 78.7 ± 4.64 63.6 ± 3.83 63.9 ± 4.73 62.4 ± 5.01 70.7 ± 2.97 75.5 ± 3.93 80.3 ± 4.02 













IVSd (mm) 1.23 ± 0.0823 
1.33 ± 




0.0803 1.4 ± 0.149 
1.45 ± 
0.0942 






























0.112 1.6 ± 0.127 






0.106 1.55 ± 0.179 










0.108 1.87 ± 0.187 











































CO: cardiac output, EDV: end-diastolic volume, EF: ejection fraction, ESV: end-systolic volume, FS: fractional 
shortening, HR: heart rate, IVSd: intraventricular septal thickness in diastole, IVSs: intraventricular septal 
thickness in systole, LVIDd: left ventricle diameter in diastole, LVIDs: left ventricle diameter in systole, 
LVPWd: left ventricle posterior wall thickness in diastole, LVPWs: left ventricle posterior wall thickness in 
systole, SV: stroke volume,  
